#version: 0.2
i n
t i
r e
t h
a n
e n
e r
e d</w>
o n
o f</w>
a t
r o
i n</w>
th e</w>
an d</w>
i t
o n</w>
a ti
s i
a s
a r
a l
s t
o r
e l
i c
a l</w>
a c
e c
d i
o l
o r</w>
re s
in g</w>
u l
e s
a s</w>
t o</w>
e r</w>
e s</w>
u c
en t
o m
p ro
u r
it h</w>
w ith</w>
p h
a m
d e
ati on</w>
o s
o c
at ed</w>
d uc
en t</w>
i d
l e
ti v
e x
a t</w>
h i
t r
o u
a n</w>
l y</w>
f f
s .</w>
c on
m e
i s
w as</w>
i c</w>
a p
o t
er e</w>
o p
in e</w>
T h
b y</w>
p res
o x
ti on</w>
i s</w>
h e
c el
a d
s u
i m
a g
w ere</w>
g en
in duc
a b
l o
th at</w>
t er
u s
u n
i l
f or</w>
p ati
u m
p er
t s</w>
ff ec
c om
t e
c h
ati on
as e</w>
i f
t re
e t
Th e</w>
v e</w>
e n</w>
in c
e p
it y</w>
at e</w>
ac tiv
p l
v er
h y
ent s</w>
e ffec
s e
si on</w>
induc ed</w>
s ,</w>
an c
a r</w>
re c
l e</w>
u t
g n
re n
r i
m ent</w>
p a
cel l
n e
ti on
n o
re as
m o
re d</w>
ti c</w>
in e
u d
l i
en c
si gn
y l
hi b
si s</w>
w e
v el
st r
an t</w>
m a
ex pres
c l
v i
tre at
pati ents</w>
0 .
t er</w>
s y
h a
in hib
m ic
y .</w>
as s
c ar
q u
an t
) ,</w>
a f
h o
on e</w>
) .</w>
- induced</w>
v e
tr an
o g
m in
th er
if ic
p re
ro u
p or
y ,</w>
ul ar</w>
res p
en d
t ed</w>
m on
tiv e</w>
an ti
t ro
e m
tran s
g h
i r
pro te
or m
c y
t o
in d
sign ific
e .</w>
b e
reas ed</w>
d os
no t</w>
I n</w>
e v
w h
treat ment</w>
expres sion</w>
b e</w>
c o
p o
es e</w>
d r
ur e</w>
th er</w>
f l
cel l</w>
p os
af ter</w>
e ,</w>
u m</w>
re g
ic al</w>
s er
e st
in g
v ed</w>
th e
ro m</w>
p ar
o b
i z
cell s</w>
d .</w>
an g
i d</w>
inhib it
f rom</w>
ou s</w>
b et
s e</w>
s p
st ud
r at
r a
g /
m or
ther ap
b u
- 1
d ro
s ho
ar e</w>
e -
oc i
effec ts</w>
ou n
id e</w>
h um
th is</w>
ep t
g rou
ti c
ar y</w>
ent r
es .</w>
re l
al ly</w>
d a
si on
resp on
enc e</w>
ass oci
en ti
in v
ation s</w>
res ul
d er
g l
re duc
le vel
S :</w>
lo w
ac t
a in
rec ept
hum an</w>
o l</w>
y p
su b
dr u
ati ve</w>
f i
m i
ti m
d ec
b l
N A</w>
de p
or y</w>
c a
O N
g h</w>
t en
c anc
0. 0
inc reased</w>
tr i
di s
effec t</w>
p ot
bu t</w>
a z
com p
tre ated</w>
hy per
un c
ol og
u re
ff e
c or
W e</w>
m ent
ox ic
u s</w>
m g/
me th
ic h</w>
g g
in ter
ant ly</w>
i th
s en
con tro
activ ity</w>
wh ich</w>
stud y</w>
associ ated</w>
ma y</w>
pa th
me t
prote in</w>
op to
y m
us ed</w>
dep end
me di
st e
f ol
sho w
o d
reg ul
ot h</w>
ec h
or s</w>
al s
e i
f orm
signific antly</w>
ap opto
th an</w>
ffe ren
u ro
car di
level s</w>
mic ro
su gg
min i
o d</w>
an al
an d
ha ve</w>
( 2
als o</w>
ation .</w>
e ar
re ase</w>
w e</w>
am in
es ,</w>
sp ec
b r
ad mini
di fferen
m at
j ec
1 0
w he
f unc
al l
i al</w>
c entr
ex pos
es t</w>
anc e</w>
i ti
de vel
sy n
al ph
d ur
be en</w>
v er</w>
ag e</w>
us e</w>
ar i
+ /
re por
th ese</w>
f act
el y</w>
c ri
e d
en z
oc y
t um
o gen
a th
k in
devel op
canc er</w>
gen e</w>
it s</w>
c he
pro duc
m y
ox id
b oth</w>
pres s
al u
a -
t ec
in f
hy dro
ha d</w>
i a</w>
u di
resul ts</w>
h as</w>
ech an
u b
recept or</w>
si st
es s</w>
dos e</w>
c ur
ut e</w>
hi gh
depend ent</w>
C Y
y s
si ve</w>
os ph
as t
a v
es s
m echan
ph en
st udi
al l</w>
u p
ne uro
ab ol
ch ang
in fl
i t</w>
ph osph
p ol
in tr
di se
t w
con centr
grou p
ver ,</w>
ob ser
b in
( 1
p r
dur ing</w>
S I
A T
c in
y s</w>
mo d
w a
mg/ k
am ine</w>
CY P
mechan is
c as
5 -
w ith
g r
at ing</w>
t oxic
ab le</w>
t h</w>
cell s.</w>
ti g
oun d</w>
b lo
s t</w>
con t
n orm
pro l
su p
s c
signific ant</w>
we en</w>
pa red</w>
- 1</w>
T hi
Th ese</w>
e th
C L
ag on
R NA</w>
bet ween</w>
therap y</w>
b i
we e
d e</w>
v ari
r on
a .</w>
gh t</w>
cy t
P A
r is
rat s</w>
rel ated</w>
ation ,</w>
t a
at es</w>
R E
es tig
cl in
show ed</w>
met abol
ro m
el ec
+/ -</w>
inv estig
m ut
M E
ou t</w>
per i
ar g
admini str
F -
m a</w>
dru g
activ ation</w>
com pared</w>
n o</w>
anal y
Thi s</w>
inc rease</w>
com bin
fol low
A C
re e</w>
I n
grou p</w>
ou r</w>
er s</w>
pati ent
ul d</w>
il ity</w>
( P
ren al</w>
respon se</w>
l in
prote in
n on
i v
- 2
tion s</w>
ocy t
1 .
ox y
blo od</w>
m un
m ol
ind ic
el l
E R
d o
b le</w>
f or
pot enti
on g
m al
si s.</w>
tion .</w>
m an
a ,</w>
tw o</w>
us ing</w>
L T
v as
f ir
dru g</w>
oc ar
e d.</w>
m ar
o ther</w>
it y.</w>
te st
i tion</w>
s ec
os e</w>
t yp
oc k
uc le
mor ph
p t
ro le</w>
al s</w>
tion al</w>
reduc ed</w>
iz ed</w>
s ur
ac tion</w>
de ter
T H
S U
vi v
O D
ve l</w>
rec ei
i r</w>
v it
re qu
ul ation</w>
path wa
d er</w>
dec reased</w>
we ver,</w>
infl am
st er
g ro
f ound</w>
tion ,</w>
oc h
mon str
m it
de monstr
inc l
li ver</w>
N A
er g
re at
a il
inv ol
m RNA</w>
id ence</w>
apopto sis</w>
n it
de f
p at
obser ved</w>
i st
om a</w>
c ol
ti s
ev alu
contro l
L -
A l
if er
mor e</w>
im mun
0 0
ac ute</w>
meth yl
olog ical</w>
SI ON
pl ic
ac id</w>
m s</w>
3 -
wee k
incl ud
ine ,</w>
C ON
5 0</w>
( A
o ph
k e</w>
m il
oc a
resp ec
sugg est</w>
contro l</w>
CL U
CON CLU
ff ic
t ing</w>
CONCLU SION
administr ation</w>
ch ol
gro w
b as
di d</w>
medi ated</w>
lo w</w>
( C
o di
re sist
treat ment
s tim
d ic
SU LT
sen si
2 -
p e
re ,</w>
clin ical</w>
el l</w>
c ul
s uc
pati ent</w>
g en</w>
pres ent</w>
pre v
y c
inhib ition</w>
expos ure</w>
on d
pol y
enz ym
s ul
ati c</w>
pro tec
mic e</w>
c an</w>
d at
RE SULT
me as
he ar
gen er
comp le
ad di
y ear
4 -
hyper ten
ac et
1 ,</w>
D NA</w>
m ot
RESULT S:</w>
c ular</w>
s ti
C D
func tion</w>
trans cri
tum or</w>
hi st
sugg est
u e</w>
i de
m ac
car cin
ris k</w>
pl as
R O
prol ifer
e t</w>
in ,</w>
th rou
ine .</w>
) -
ot yp
a c</w>
pl a
it e</w>
ou s
os t</w>
respec tiv
norm al</w>
5 0
mar k
m g</w>
ME TH
wh o</w>
in jec
H o
in -
un der
en h
chang es</w>
sion .</w>
w ell</w>
the ir</w>
ant agon
ma in
2 .
l as
1 0</w>
E C
he pati
tr ac
METH OD
pl ac
studi es</w>
f er
on ly</w>
id enti
a x
st res
por t
e tic</w>
f ail
i es</w>
P -
sy m
y l</w>
om e</w>
n ucle
b ind
th i
grow th</w>
bl ock
c e
transcri p
alph a</w>
ab ility</w>
c al
b ro
respectiv el
Ho wever,</w>
c at
re t
ch ron
c e</w>
e u
est er
i p
no w
l oc
v id
activ e</w>
fact or</w>
si ble</w>
fl u
dat a</w>
inc reas
hi gh</w>
in al</w>
el ial</w>
k now
a ffec
toxic ity</w>
f e
u red</w>
( M
c hi
le u
ure s</w>
inhibit ed</w>
se qu
throu gh</w>
s )</w>
potenti al</w>
m ul
( 3
oc cur
P C
T o</w>
o -
I I
sy st
y -
is m</w>
an im
C A
dise as
se v
ver se</w>
sion ,</w>
ass a
pt om
high er</w>
il l
inflam mat
S T
cy c
ser um</w>
enh anc
V E
ox ic</w>
r ate</w>
anti -
entr ic
ocar di
f ind
ent ly</w>
tis su
typ e</w>
o id</w>
vas cular</w>
c oca
stim ul
o ver
an e
inflammat ory</w>
1 -
o th
re le
5 %</w>
ca used</w>
m ost</w>
im pro
gen es</w>
u r</w>
press ure</w>
hear t</w>
whe n</w>
tim e</w>
he pat
pres sion</w>
METHOD S:</w>
suc h</w>
sign al
po si
at ory</w>
v ing</w>
dise ase</w>
A P
bind ing</w>
ur on
d ys
a di
on g</w>
do w
ain ed</w>
chron ic</w>
syn dro
pro g
y r
mon th
% )</w>
ar ac
d am
ous ly</w>
l un
co uld</w>
regul ation</w>
er .</w>
' s</w>
ex amin
c um
it y,</w>
plas ma</w>
ox ide</w>
if ic</w>
enc y</w>
N -
induc tion</w>
s h
1 )</w>
v entric
ing s</w>
che mo
analy sis</w>
hydro x
follow ing</w>
T I
th ou
cardi ac</w>
2 ,</w>
l ess</w>
dos es</w>
or al</w>
o re
da y</w>
d el
v en
car b
im port
an e</w>
d es
N F-
at ro
th ree</w>
s elec
0 0</w>
as e-
e ffic
mg/k g
pro mot
op ath
b ut
ar ter
spec ific</w>
y n
inhibit or</w>
ti n</w>
concentr ations</w>
rat s.</w>
f r
z ed</w>
si s,</w>
in to</w>
ine -induced</w>
ag ain
le vel</w>
b ra
s ed</w>
ed ,</w>
op er
si mil
( H
d ,</w>
se iz
develop ed</w>
again st</w>
effec t
ati n</w>
c ase</w>
includ ing</w>
si de</w>
da ys</w>
c i
( T
d ue</w>
x im
gl uc
n ec
sub jec
er al</w>
sym ptom
ti s</w>
p er</w>
with out</w>
( S
th ose</w>
fi ed</w>
f u
o id
as t</w>
ot oxic
hi le</w>
ro s
c ap
ogen e
ei ther</w>
pro st
ell ular</w>
combin ation</w>
in .</w>
mechanis m</w>
d s</w>
an ts</w>
re as</w>
mo de
therap eu
in j
R P
de tec
kin ase</w>
t arg
re ve
R A
per im
G F
repor ted</w>
mol ec
( P</w>
fir st</w>
ri al</w>
plac e
dec rease</w>
pr im
pre vi
ventric ular</w>
for e</w>
ne ph
gl ut
po st
phosph or
leu k
mod el
develop ment</w>
em ia</w>
l at
m us
differen t</w>
3 .
b reas
non -
mg/k g</w>
om e
iti es</w>
i on
l or
i .
thou gh</w>
mode l</w>
s am
arac ter
cont in
erg ic</w>
si a</w>
inj ur
bet a-
li p
al ed</w>
ine -
U N
i l</w>
l im
CYP 2
a in</w>
demonstr ated</w>
m is
oxid ative</w>
lun g</w>
1 2
therapeu tic</w>
breas t</w>
investig ated</w>
recei ved</w>
b enz
f ur
invol ved</w>
och ond
ep ti
ang i
ot al</w>
f requ
differen ti
um b
syst em
ch aracter
l y,</w>
en s
i ly</w>
est ro
r at</w>
u al</w>
le p
deter min
is h
com par
find ings</w>
l it
k ing</w>
se ver
treatment .</w>
ing .</w>
0.0 0
r o</w>
phosphor yl
low er</w>
ex perim
ra ph
ol d</w>
g e
contin u
place b
f o
1 9
- 2</w>
M P
sev ere</w>
O ur</w>
stud y,</w>
simil ar</w>
me m
sion s</w>
ass ess
ac h</w>
activ ated</w>
l ine</w>
az ol
di vid
CONCLUSION S:</w>
mit ochond
effec tive</w>
know n</w>
ic in</w>
cell s,</w>
import ant</w>
dow n
w hile</w>
b le
drug s</w>
in iti
1 A
d om
( N
ent ed</w>
reduc tion</w>
( I
v alu
ap pro
my ocardi
ar mac
me an</w>
admini ste
hy po
m e</w>
c is
poly morph
form ation</w>
l os
di st
ep i
at ten
repor t</w>
expos ed</w>
is t</w>
t ac
whe ther</w>
patient s.</w>
ol ic</w>
al ter
( D
con tr
fi bro
mechanis ms</w>
sur viv
mul ti
F ur
ver atro
el ev
therap y.</w>
com m
vit ro</w>
stres s</w>
t ol
reve aled</w>
d op
effic ac
h al
ar sen
ur al</w>
g iv
D :</w>
l ed</w>
signal ing</w>
c le
ne uron
v al
cul t
3 ,</w>
dis or
4 .
whe reas</w>
ain ing</w>
A n
def ic
t otal</w>
per form
y ing</w>
con cl
M C
or -
administe red</w>
group s</w>
ar r
l ong
f am
hepati c</w>
vi a</w>
1 2</w>
end oth
on e
regul ated</w>
ou t
cas p
is o
ex c
pro c
ap pa
str uc
K G
show n</w>
ren t</w>
p 5
0.0 5
it ed</w>
inf u
ac id
we i
l d
T -
dos e-
week s</w>
a w
neph ro
examin ed</w>
C O
ad e</w>
6 -
and om
prog res
a m</w>
meas ured</w>
o sis</w>
re x
n umb
st at
cas es</w>
enzym e</w>
s es</w>
bra in</w>
re ver
pa in</w>
B AC
coca ine</w>
n er
1 7
ma j
trans por
con tri
i red</w>
d ing</w>
m ic</w>
giv en</w>
- dependent</w>
( G
ter m</w>
ad en
en e
d -
b od
RO UN
KG ROUN
BAC KGROUN
f t</w>
ste m</w>
t ly</w>
I t</w>
C a
cy cl
C h
w or
p sy
fur ther</w>
M D
p ine</w>
resist ance</w>
ph armac
da y
2 4</w>
i g
lo ro
b ec
s ing
r andom
k ine
S )</w>
ad verse</w>
w om
tic al</w>
ha vi
ure .</w>
induc e</w>
di rec
sup press
be fore</w>
deter m
g reat
produc tion</w>
ent al</w>
g am
cell ular</w>
I I</w>
( -
concentr ation</w>
di ab
2 0</w>
mic e.</w>
intr av
myocardi al</w>
con di
2 0
atten u
I L
en e</w>
cat al
ic ally</w>
es the
b il
ad ren
elec tro
sho w</w>
og raph
id ine</w>
ph y
ep ith
am ide</w>
acet yl
re st
tiv ity</w>
th ere</w>
ro ph
f ic
5 .
evalu ated</w>
li ke</w>
a d</w>
pl e</w>
o ver</w>
syn the
enhanc ed</w>
vi r
prim ary</w>
hy th
d ox
p ul
R )</w>
s al
ch lor
comp oun
% ,</w>
ev idence</w>
be havi
m ents</w>
indic ate</w>
] .</w>
A N
3 0</w>
pl at
gl yc
O B
us ,</w>
t ub
at h</w>
el i
M A
8 -
ing ,</w>
B P
ap p
ve ment</w>
pathwa y</w>
c r
a ut
gen otyp
iz ation</w>
produc ed</w>
ca use</w>
r ic</w>
al e</w>
efficac y</w>
prolifer ation</w>
inc idence</w>
l ym
with in</w>
fail ure</w>
identi fied</w>
pres ence</w>
( 4
or g
im pa
i ed</w>
id ne
ac tions</w>
J EC
otoxic ity</w>
Fur ther
ish ed</w>
ocyt es</w>
az ep
de ath</w>
apopto tic</w>
oc he
li g
intr ac
2 )</w>
f ac
n ic
mic al</w>
10 0</w>
a use</w>
or ub
chi ld
determin ed</w>
protec tive</w>
c op
bod y</w>
1 ).</w>
syndro me</w>
s m
posi tive</w>
respectivel y.</w>
ec ted</w>
th rom
cy to
ath i
C C
mem br
in divid
I L-
BACKGROUN D:</w>
w ar
nucle ar</w>
A D
my el
k ed</w>
maj or</w>
OB JEC
trans fer
hy p
par tic
associ ation</w>
TI VE
M T
intrav en
at al</w>
tol er
ne w</w>
k idne
di ag
r ati
nec ro
D E
r ang
am p
at ely</w>
f em
1 4
k e
no vel</w>
CONCLUSION :</w>
OBJEC TIVE
pro f
A c
des cri
si de
l u
mitochond rial</w>
A B
v ul
epi lep
dam age</w>
v ol
A d
bet a</w>
numb er</w>
norm al
m ou
symptom s</w>
R -
veratro l</w>
inhibit or
ver y</w>
A L
om er
a u
resul ted</w>
s ing</w>
gen ic</w>
infl u
1 /
increas es</w>
Th ere</w>
comple t
j u
ab l
N T
injec tion</w>
6 .
tic s</w>
studi ed</w>
s ol
hy pot
( E
ac h
flu o
5 ,</w>
c er
- term</w>
lym ph
on ic</w>
et y</w>
an y</w>
u p</w>
a k
H e
t u
alph a-
inhibit ors</w>
bas ed</w>
E x
alph a
determ ine</w>
throm b
b ility</w>
i a.</w>
ear ly</w>
s hi
recei ving</w>
previ ously</w>
induc es</w>
f our</w>
con fir
month s</w>
protein s</w>
ogene sis</w>
in ary</w>
activ ity.</w>
gen etic</w>
addi tion,</w>
P ro
k appa
S -
mal e</w>
great er</w>
he al
olog y</w>
hypot en
p ac
mo re,</w>
is ol
endoth elial</w>
sever al</w>
al ,</w>
N O
perform ed</w>
pos sible</w>
s k
transcrip tion</w>
M )</w>
mon ary</w>
9 5%</w>
re main
( p</w>
tissu e</w>
mo di
a sis</w>
o tic</w>
on ary</w>
c es</w>
recept ors</w>
A f
A -
p le
an n
molec ular</w>
i gn
I F
w il
mi a</w>
n i
all el
ane ous</w>
at or</w>
assess ed</w>
Af ter</w>
r ine</w>
g as
m .</w>
ra di
t ained</w>
t oxic</w>
Further more,</w>
s on
s ome</w>
f ul
rele ase</w>
l ab
anim als</w>
sho uld</w>
ret in
eth yl
ac cum
defic i
hydrox y
1 5</w>
(2 )</w>
in -induced</w>
psy ch
A )</w>
selec tive</w>
mut ations</w>
phosphoryl ation</w>
at ed.</w>
ec t
S C
p p
e ment</w>
6 0</w>
da ily</w>
p ir
po in
fact ors</w>
l arg
e ach</w>
antagon ist
ho ur
A s
ment al</w>
in sul
ti al</w>
o ve
comm on</w>
ce re
( B
pro v
arr hyth
sing le</w>
investig ate</w>
com plic
ar c
p ri
anti oxid
r ap
subjec ts</w>
sy stem</w>
respon ses</w>
7 .
cyc lo
mod ul
suggest ing</w>
s odi
se t</w>
1 8
sensi tivity</w>
om y
- old</w>
d ed</w>
ar ly</w>
t ,</w>
c oun
nit ro
hyperten sive</w>
injur y</w>
dox orub
ogen ic</w>
olog ic</w>
C om
surviv al</w>
high -
p op
ne g
ph eral</w>
resist ant</w>
an s</w>
ocyt e</w>
m in</w>
ar b
C on
epith elial</w>
re tion</w>
T w
R NA
viv o</w>
ex trac
mou se</w>
occur red</w>
s -
fu l</w>
Al though</w>
am in</w>
bet a
phy si
cor onary</w>
( 0.
re vi
pot ent</w>
s it
metabol ism</w>
targ et</w>
( L
och rom
mi ght</w>
k g
dr aw
or s.</w>
A I
expres sed</w>
( O
on e,</w>
S H
tiv ely</w>
ation s.</w>
v es</w>
p yr
h or
cal ci
c le</w>
0 %</w>
s el
am ph
ol ,</w>
follow ed</w>
am ong</w>
ex hib
er ,</w>
d ou
los s</w>
tr ic</w>
as e,</w>
c -
op las
C I
i on</w>
th al
me dic
ta ke</w>
us e
con vul
4 ,</w>
6 ,</w>
prost ate</w>
bas el
expres sion.</w>
e g
s :</w>
S E
disor der
combin ed</w>
intraven ous</w>
- treated</w>
1 3
al .</w>
ab s
ren ce</w>
le ft</w>
inflam m
chang e</w>
PA R
con sist
cardi o
le ad
m ed</w>
phen yl
0 ,</w>
yc in</w>
ag ents</w>
t est</w>
peri pheral</w>
pul monary</w>
ca us
( n</w>
y ed</w>
pe a
ph ase</w>
casp ase-
differen ces</w>
detec ted</w>
diseas e.</w>
1 ,
r h
athi one</w>
s y</w>
p5 3</w>
fol d</w>
e re
chol ester
ol e</w>
ag ent</w>
sensi tive</w>
an esthe
un der</w>
dec reas
sup por
' -
mus cle</w>
as es</w>
pre dic
mol /
s af
a i
gr am
S t
wee k</w>
de x
ab il
ox if
on e.</w>
A M
(2 )
qu in
p it
sodi um</w>
struc t
patient s,</w>
placeb o</w>
al -
elev ated</w>
R es
cyc le</w>
infu sion</w>
su per
demonstr ate</w>
canc er.</w>
hyperten sion</w>
lin es</w>
with draw
h om
H C
tri al</w>
vari ous</w>
lo b
col l
sc op
vel y</w>
year -old</w>
ochrom e</w>
all y,</w>
sm all</w>
1 5
ex er
1 .</w>
pl ant
OBJECTIVE :</w>
oxy gen</w>
as s</w>
t y</w>
m el
in dependent</w>
ud e</w>
ad ul
glut athione</w>
pro per
( +
i a,</w>
ab ly</w>
m es
lip id</w>
tic ally</w>
is che
ac in</w>
estro gen</w>
org an
hypo the
I C
1 6
o st
H T
t op
al one</w>
inhibit ory</w>
ur ine</w>
sul f
compoun ds</w>
ag ent
pro p
t al</w>
p ec
cor rel
activ ities</w>
man n
P )</w>
g o
func tional</w>
stimul ated</w>
en g
P 4
r an
re n</w>
f low</w>
res veratrol</w>
membr ane</w>
( -1
f ree</w>
G F-
su s</w>
ur inary</w>
prol ong
inhib it</w>
g er
wei ght</w>
E ffec
yn am
s mo
sh or
m en
ph al
carcin oma</w>
Al l</w>
o z
ro l
si c</w>
y sis</w>
fi br
pla y</w>
e ter
c ir
year s</w>
re active</w>
bec ause</w>
arsen ic</w>
ot oxic</w>
u res
oxy gen
seiz ures</w>
tum ors</w>
2 5</w>
O n
o ti
in test
CYP 1A
8 .
cyt ochrome</w>
vit amin</w>
st and
m er
multi ple</w>
su sc
ti me
sam e</w>
susc epti
experim ental</w>
neuro path
o ver,</w>
polymorph is
s om
agon ist
promot er</w>
t s.</w>
im plic
P G
lo g
ster oid
ox i
ast ,</w>
cont aining</w>
ogen ous</w>
tran si
g/ m
inf arc
gr ad
e qu
rec ur
der i
b ed</w>
arter ial</w>
P T
4 0</w>
tro ph
ho wever,</w>
b ac
o f
antagon ist</w>
r up
inhibit s</w>
3 A
ag es</w>
amph et
an dro
2 9
necro sis</w>
te m
M ore
br al</w>
per c
ri l</w>
reat ment</w>
N o</w>
og e
nic ot
prof il
con duc
n at
dop amine</w>
p .
long -term</w>
affec ted</w>
( R
N F
child ren</w>
the re
b ene
1 ),</w>
ti co
pl us</w>
mal ign
c it
i um</w>
stud y.</w>
er at
calci um</w>
More over,</w>
intrac ellular</w>
y ro
o .</w>
for m</w>
D -
1 6</w>
gener ation</w>
1 4</w>
test ed</w>
rati o</w>
up -
g u
deri ved</w>
transfer ase</w>
kidne y</w>
ar t
proper ti
ox in</w>
IL -1
N e
enc ed</w>
A t</w>
t al
ver sus</w>
qu anti
7 -
2 ,
al lo
pre g
C -
trans f
C B
chemo therapy</w>
cardio vascular</w>
g li
bl ad
prov ide</w>
P ati
centr al</w>
metabol it
te red</w>
P h
apopto sis.</w>
ot ens
indic ated</w>
f en
ar d</w>
K -
opath y</w>
m uc
oc c
mg/kg )</w>
antioxid ant</w>
ad v
y g
suggest ed</w>
evalu ate</w>
ove rex
D )</w>
activ ity,</w>
2 .</w>
e str
app ear
contr ast,</w>
or ph
gl omer
gen e
individ u
ol ol</w>
tr a
t .</w>
e l</w>
basel ine</w>
enzym es</w>
neg ative</w>
assa y</w>
immun o
pro b
B cl
sec ond
oc k</w>
met ast
is tic</w>
8 ,</w>
ation shi
G S
sti tu
res t</w>
sub st
ati s
enti al</w>
stat us</w>
ro p
fem ale</w>
f y</w>
prev ented</w>
ic e</w>
est abl
dis continu
N P
inf ec
t -
mon it
ble -
v ast
as si
affec t</w>
D i
0 -
T reatment</w>
ation al</w>
s o
C l
tac hy
suggest s</w>
concl u
and /
re s</w>
heal th
m g
i ous</w>
tion s.</w>
attenu ated</w>
y st
ob tained</w>
and/ or</w>
m al</w>
o d.</w>
treatment ,</w>
suppress ed</w>
dose- dependent</w>
valu es</w>
de ath
( V
peri od</w>
y tic</w>
on set</w>
ol .</w>
effect s.</w>
e ti
ma xim
differen ce</w>
confir med</w>
rel ationshi
par am
le ast</w>
mut ation</w>
system ic</w>
AN D</w>
inter action</w>
z e</w>
addi tion</w>
vi ron
u preg
ti l
di pine</w>
oper id
as pir
P ar
B oth</w>
et al</w>
H ep
oche mical</w>
er s.</w>
low -
co ur
group .</w>
toxic ity.</w>
1 1</w>
li k
on t
kin son
p 3
li thi
dou ble-
sk in</w>
pathwa ys</w>
Th us,</w>
ra z
cardi a</w>
recept or
fi ve</w>
te d.</w>
down -
on in</w>
cl on
A R
3 )</w>
o ste
+/ -
c an
al s.</w>
p -
ex peri
cor related</w>
A S
impa ir
Pati ents</w>
2 5
D O
e )</w>
molec ul
se en</w>
impro ved</w>
angi otens
re action</w>
hepati tis</w>
ev ents</w>
y th
metabol ic</w>
the y</w>
CO X
out com
pat ter
dam ag
f ar
character ized</w>
( F
w at
P I
sub sequ
ag g
ab out</w>
resul t</w>
me n</w>
A ,</w>
control led</w>
P D
inter v
kappa B</w>
sam pl
z ap
includ ed</w>
en d</w>
ter min
G T
s ;</w>
p ur
influ ence</w>
D H
oph ag
direc t</w>
L P
level s.</w>
group s.</w>
blad der</w>
mg/ m
stim ulation</w>
mo der
en viron
xim ately</w>
si x</w>
S O
n os
accum ulation</w>
requ ired</w>
revi e
o ic</w>
hal operid
A r
phen otyp
on d</w>
glyc er
cl er
am eth
ta k
si d
t oge
M M
cur rent</w>
ch loro
n ot
ide ,</w>
gluc ose</w>
polymorphis ms</w>
caus es</w>
f oc
op i
or i
frequ ency</w>
amin o
bi o
is on</w>
res c
A s</w>
9 .
transcrip tional</w>
ex p
sti l
st ri
immun e</w>
pl atin</w>
k et
hour s</w>
ro n</w>
N S
G F</w>
pro vid
fo re,</w>
spec ies</w>
dys function</w>
inc e</w>
u s.</w>
pres su
diab etic</w>
G N
at e,</w>
st re
ai m</w>
ure ,</w>
T NF-
syndro me
per oxid
wom en</w>
v is
micro gram
y e
hi pp
b one</w>
gam ma</w>
I m
sub str
pol ym
T CD
l ac
oc amp
s a
b ute</w>
ac t</w>
func tion.</w>
and ,</w>
mg/kg ,</w>
intest inal</w>
pos si
G ST
s ).</w>
reg ion
in s</w>
er yth
p epti
cardi omy
t am
o s</w>
ch ain</w>
st ro
th en</w>
v s.</w>
isol ated</w>
p i
cl u
ed ly</w>
op en
3 ,
health y</w>
param eter
ent .</w>
appro ximately</w>
2 1</w>
s /
os pit
l if
H O
H -
P A</w>
L )</w>
k n
contri bute</w>
comple x</w>
mac roph
W he
v ant</w>
ex pl
hipp ocamp
as th
0.05 ).</w>
pre treatment</w>
CYP 3A
A k
l ying</w>
high ly</w>
al tered</w>
morph ine</w>
n a
dur ation</w>
d og
increas ing</w>
( 5
in ine</w>
he ter
pos e</w>
syn th
H B
con side
diab et
H g
nit ric</w>
gam ma
per id
cholester ol</w>
ab normal
su m
double- bl
cult ured</w>
M e
analy zed</w>
re pe
em ic</w>
methyl ation</w>
R e
c reat
under lying</w>
an th
CYP2 C
8 0</w>
cere bral</w>
mor tal
oz yg
C )</w>
p rec
control s</w>
up take</w>
- related</w>
1 3</w>
si l
R ec
n ing</w>
AT P
str ic
pri or</w>
h er
. ,</w>
ad ju
p anc
neuron al</w>
ev en</w>
a re
ar di
T R
C R
r u
con ver
con f
7 ,</w>
al though</w>
anal ys
1 8</w>
conclu sion,</w>
qu er
ent ,</w>
ac hi
ation s,</w>
os om
iti s</w>
W ester
complet e</w>
2 /
3 4
om eth
pre gn
os ine</w>
synthe sis</w>
previ ous</w>
ti z
polym er
P PAR
ve d.</w>
in ten
alter ations</w>
c ut
insul in</w>
obser v
medi an</w>
sp ont
( 6
e de
lik ely</w>
wil d-
c ros
arter y</w>
in d</w>
b a
um .</w>
ati vely</w>
P4 50</w>
m ,</w>
de g
m am
st ar
block ed</w>
rang e</w>
fluo ro
hypoten sion</w>
car ri
di et
c ess
leuk emia</w>
dom in
2 4
) )</w>
mark edly</w>
c h</w>
ex t
Wester n</w>
ine ph
A n</w>
resul ting</w>
fact or
vit ro
estr adi
p u
do es</w>
differenti ation</w>
- mediated</w>
sec retion</w>
pop ul
de hy
man y</w>
as e.</w>
-1 ,</w>
R A</w>
al ized</w>
) ;</w>
exhib ited</w>
mark ed</w>
diag nos
fic ation</w>
be ing</w>
mon o
a ff
doxorub icin</w>
SI GN
i f</w>
H D
P re
3 .</w>
w id
S er
tim es</w>
rel ative</w>
ynam ic</w>
random ized</w>
rec or
polymorph ism</w>
indic ating</w>
A h
progres sion</w>
a si
diag no
R ,</w>
le sions</w>
enc e
ur ing</w>
ur ia</w>
withdraw al</w>
i od
I N
% ),</w>
reduc e</w>
fl av
gas tric</w>
z in
anc ed</w>
L D
wild- type</w>
anal ge
O n</w>
oper ative</w>
relationshi p</w>
it az
respectivel y
I )</w>
p tion</w>
group ,</w>
G rou
( p
st atis
i an</w>
ma in</w>
wei gh
l and
gl itaz
expres sion,</w>
M AP
G 2</w>
inc ub
sequ enc
trans plant
t s,</w>
i ble</w>
8 0
ster one</w>
conside red</w>
d oc
v s</w>
super oxide</w>
9 ,</w>
lit ax
y s.</w>
k al
in te
d ul
pres ented</w>
H S
D P
fact or-
2 00
fibro bl
agon ist</w>
sec ond</w>
model s</w>
dis rup
ocar cin
Tw o</w>
) -induced</w>
1 B
de oxy
le v
ad y
str ong
respon se
resp ir
om as</w>
ke y</w>
k ine</w>
h ospit
at ors</w>
ce tin</w>
comp on
ch rom
av ail
estro gen
comp an
ameth as
5- F
second ary</w>
ide .</w>
rat es</w>
th yro
neuron s</w>
E n
(2 +
fl ur
tam oxif
respon sible</w>
abs ence</w>
r ing</w>
fam ily</w>
is on
ass ess</w>
si m
pla ys</w>
h ex
anti- inflammatory</w>
A K
l ast
al dehy
m m</w>
c ad
PC R</w>
targ et
g lob
vast atin</w>
C P
is h</w>
c lo
al co
prolong ed</w>
cis platin</w>
malign ant</w>
inflamm ation</w>
fu sion</w>
anim al</w>
control s.</w>
der iv
Th ere
O R
H I
plat el
sign ed</w>
rat s,</w>
ess ential</w>
ER K
te n</w>
ac compan
on ucle
ther ,</w>
4 8</w>
de grad
week s.</w>
lead ing</w>
o ur
meas ure
glut am
sp inal</w>
n al</w>
5 )</w>
p ite</w>
ment .</w>
suscepti bility</w>
ograph y</w>
addi tional</w>
% ).</w>
adul t</w>
del a
oc or
2 7
ence phal
um ,</w>
it al</w>
l y
gr an
de press
3 0
1 %</w>
identi fy</w>
he mat
ye ar</w>
par ti
em br
1 7</w>
suppor t</w>
oca ine</w>
hi z
x en
reduc t
protec tion</w>
B -
h loro
cop per</w>
anc e.</w>
im en
sur ger
r ac
an a
t oc
ine d.</w>
contri but
. 0
at ric</w>
use ful</w>
pathwa y.</w>
initi al</w>
prev en
pr an
fe at
f at
proc ess
respectivel y,</w>
ap pea
hyper troph
genotyp e</w>
br ady
properti es</w>
azol e</w>
ar th
p il
impro vement</w>
(1 )</w>
P K
therap y,</w>
prev ent</w>
ti s.</w>
mat ri
le ad</w>
o ,</w>
eth an
polymer ase</w>
gl y
sup ple
pres ent
al ge
i es.</w>
ne l</w>
complet ely</w>
ta in</w>
inhibitor ,</w>
inter fer
N a
partic ul
ent an
E R</w>
-2 -
t ur
enc od
a ver
ag e,</w>
le ar
reg ion</w>
bu tion</w>
On e</w>
en ing</w>
comp ound</w>
1 9</w>
w ell
end ogenous</w>
C o
i ally</w>
J N
col on</w>
o red</w>
compar ison</w>
ment ation</w>
ol -induced</w>
ures .</w>
o vari
fam il
individu als</w>
ex tr
war far
spec ific
mis sion</w>
ind ometh
T )</w>
embr y
un d
moder ate</w>
pac litax
m m
ag land
mil d</w>
lin ked</w>
mot or</w>
hum an
wat er</w>
m ag
it one
ap plic
consist ent</w>
i. v
saf ety</w>
cap sa
ul ated</w>
extrac ellular</w>
rec over
an nel</w>
angiotens in</w>
n .</w>
cy ste
inv a
dep le
sampl es</w>
lig and
interv al</w>
bi op
or ing</w>
eryth ro
L C
d ens
10 (-
sup pression</w>
s co
ch annel</w>
R .</w>
orm one</w>
O X
u tion</w>
s ite</w>
larg e</w>
kn ock
injec ted</w>
arrhyth mi
disor der</w>
Whe n</w>
ner v
6 )</w>
di ff
le ,</w>
sc hiz
s ),</w>
phosph ate</w>
om a.</w>
b -
art an</w>
phen y
it ing</w>
seiz ure</w>
at e.</w>
m RNA
per sist
duc tion</w>
( 7
B P</w>
cyclo phosph
amphet amine</w>
H g</w>
respir atory</w>
i di
in de
az ine</w>
post -
accompan ied</w>
ne ut
ffic i
4 )</w>
quanti t
anal og
er ing</w>
micro M</w>
me mor
or der</w>
h ormone</w>
mel an
invol vement</w>
re d.</w>
3 %</w>
2 %</w>
cyt otoxicity</w>
in i
r s
b o
N O</w>
t y
There fore,</w>
remain ed</w>
f -
. )</w>
sc re
induc ing</w>
pil ocar
le .</w>
p y
if e
cour se</w>
cle ar
lo l</w>
( i
o p</w>
ful ly</w>
O -
parameter s</w>
spec tive</w>
op o
diagno sis</w>
zin c</w>
oti de</w>
co -
transpor t</w>
C S
l id
hyper alge
appear s</w>
mut ant</w>
metabolit es</w>
hist ory</w>
ev ed</w>
am id
og en</w>
mi x
day s.</w>
correl ation</w>
am ycin</w>
rever sed</w>
5- HT
syst olic</w>
oph ren
mann er.</w>
m id
de hydro
hydrox yl
In c
re pa
ocyt es.</w>
end ed</w>
th us</w>
k g</w>
l y.</w>
dys kine
( 50
om ic</w>
o sis.</w>
ar rest</w>
G -
ph yl
co gn
ser ot
g ra
st age</w>
expres sing</w>
COX -2</w>
tub ul
P R
syn erg
bas al</w>
appea red</w>
su ffici
ster oid</w>
che mical</w>
e -induced</w>
adv anced</w>
r f
li po
U sing</w>
aspir in</w>
C T
A .</w>
administr ation.</w>
cri tical</w>
ar ra
follow -
(1 0</w>
dex amethas
over all</w>
dis c
neuro log
NF- kappaB</w>
i qu
cyto kin
allel e</w>
S .</w>
di l
aff in
si a.</w>
schiz ophren
y cl
subsequ ent</w>
conduc ted</w>
synth ase</w>
al ysis</w>
ri tis</w>
lithi um</w>
st ained</w>
he mor
h ic
es tim
prost agland
E T
mic e,</w>
iz e</w>
decreas es</w>
E )</w>
H y
Effec ts</w>
S im
fic ial</w>
behavi oral</w>
p ent
com it
activ ation.</w>
ap er
E 2</w>
level s,</w>
b er</w>
com mon
hor mon
ex ten
defici ency</w>
G AB
hemor rh
RO S</w>
ner ve</w>
s ep
cor e</w>
B a
fibr ill
t y-
str at
9 0</w>
catal ep
dist ri
b or
b is
chlor ide</w>
medi ate</w>
cont ent</w>
concl ude</w>
-1 -
par tial</w>
es pec
C N
P U
li ght</w>
del i
man ag
MC F-
st ate</w>
C H
(3 )</w>
il tr
ep id
carb on</w>
panc re
p3 8</w>
iz ing</w>
ev ent
a or
espec ially</w>
zap ine</w>
es tic
% .</w>
che mic
b al
or e</w>
M ,</w>
di et</w>
lit erat
trans loc
re ac
at or
w o
a ro
dow n</w>
bil e</w>
at eral</w>
ot rex
mg/k g/
k s</w>
peri od
k ers</w>
n ess</w>
cut aneous</w>
I P
o kine
3 5
mark ers</w>
individ ual</w>
- like</w>
ty ros
am y
he ad
effect .</w>
fail ure.</w>
s in
vol um
sever ity</w>
hypothe sis</w>
re tro
prog ester
min ut
os cler
bl ock</w>
tub ular</w>
transpor ter</w>
a ther
ep is
descri bed</w>
2 O
b ol
D NA
lin ical</w>
i. p.
R T-
-1 )</w>
o gn
inhibit ing</w>
pyr id
remain s</w>
leu kin
gr ade</w>
He re,</w>
8 %</w>
ta king</w>
S M
partic ip
ocy tic</w>
def ec
x i
pro -
AC h
wa y</w>
i tive</w>
5 4
ob arb
hy dr
G l
clin ically</w>
res h
pro po
ane ously</w>
drug s.</w>
contr ast</w>
b ly</w>
wid ely</w>
de pres
reduc es</w>
coll ag
ad he
rap id</w>
p en
re actions</w>
min im
b odi
In hib
quer cetin</w>
ot rop
F or</w>
recept or-
er s,</w>
rec ently</w>
strat eg
retin oic</w>
metabol is
0.05 )</w>
M T</w>
mi gr
li ver
ex amine</w>
i ron</w>
9 -
methyl -
establ ished</w>
fluo resc
environ mental</w>
impa ired</w>
micro scop
glomer ular</w>
phosph at
ve hic
tion s,</w>
oc l
or s
effic i
cyt otoxic</w>
antagonist s</w>
gran ul
li gh
doxorub ic
t le</w>
fr act
a )</w>
Grou p</w>
wo uld</w>
res ol
repor ts</w>
path ogenesis</w>
par t</w>
ovari an</w>
stre am</w>
R S
on e-
fr ag
at rial</w>
sub un
al ine</w>
prote ren
sen s
pro pran
overex pression</w>
fibro sis</w>
F )</w>
stil l</w>
adren ergic</w>
inde x</w>
2 6
end ome
re verse</w>
glitaz one</w>
vari ants</w>
pro mis
am oun
ann el
rec ogn
infarc tion</w>
epis od
el ic
transi ent</w>
reduc ing</w>
direc tly</w>
dehydro gen
Par kinson
5 7
estradi ol</w>
NO S</w>
strong ly</w>
S e
n ife
implic ated</w>
defici ent</w>
G en
par t
o v
nicot ine</w>
fat ty</w>
ti zed</w>
micro som
induc ible</w>
tachy cardia</w>
br on
ain s</w>
se d.</w>
respon sive</w>
NF- k
D C
B ec
injur y.</w>
in ic</w>
ch annel
di ast
chol est
tissu es</w>
statis tically</w>
n or
produc e</w>
valu e</w>
em ia.</w>
b ri
Hep G2</w>
s oci
E -
l am
all eng
e ts</w>
Ac ute</w>
termin al</w>
C I</w>
4 0
2 ).</w>
reg i
oc ellular</w>
ing ly,</w>
depend ently</w>
2 00</w>
mitochond ri
up on</w>
um -
p iv
o si
convul s
amin ergic</w>
A H
( 1</w>
r ad
osom al</w>
neuropath y</w>
poin t</w>
S R
f le
ozyg ous</w>
mi um</w>
cur ren
N rf
on -
oc ic
con comit
U GT
tri gg
A R</w>
0.0 00
u su
typ es</w>
obser ved.</w>
ei ght</w>
a ir
pre -
high- dose</w>
warfar in</w>
under st
sequ ence</w>
sal ine</w>
ob jec
hyperten sion.</w>
expos ure.</w>
cyt os
2 3
reduct ase</w>
( 10
nerv ous</w>
f ed</w>
diabet es</w>
II I</w>
(P <
T ran
( n
t ech
pharmac ological</w>
2 ),</w>
impair ment</w>
form s</w>
model .</w>
benz o
at ed,</w>
s et
o ff
dos age</w>
e very</w>
f entan
meth otrex
cis plat
disc us
con trac
mortal ity</w>
alter n
sign al</w>
posi tion</w>
per ox
frequ ently</w>
L ,</w>
8 )</w>
(1 .
m l
bi om
preven tion</w>
ch alleng
O f</w>
ot or</w>
t e</w>
experi enced</w>
evalu ation</w>
a qu
7 0</w>
y oun
n al
im in
Ak t</w>
di d
ob las
man if
inter leukin
ineph rine</w>
c al</w>
st able</w>
2 8</w>
syndrome .</w>
le -
E P
ho l</w>
character is
ch ro
M B
recover y</w>
caspase- 3</w>
to war
bi ochemical</w>
tak en</w>
ris perid
oid s</w>
I S
r it
sensi tiz
sev en</w>
h e</w>
E 1</w>
w ide</w>
physi ological</w>
def in
ocor tico
(2) O
regul atory</w>
dis mut
comple x
tr ic
reg res
death .</w>
tamoxif en</w>
am iod
quantit ative</w>
con stitu
amiod ar
M S
sur fac
subst anti
oc ept
AT I
re sid
creat inine</w>
agonist s</w>
of ten</w>
lab or
exc retion</w>
bi ological</w>
lin es.</w>
SE :</w>
cogn itive</w>
transf ected</w>
as .</w>
stand ard</w>
diast olic</w>
nec ess
t om
rever sible</w>
o ked</w>
TCD D</w>
E GF
d ine</w>
m an</w>
e ff
au th
2 3</w>
si zed</w>
regul ates</w>
if ied</w>
repor ter</w>
nephro path
m ass</w>
aut o
viv o.</w>
prolifer ative</w>
oph yl
blo t</w>
MCF- 7</w>
vitro .</w>
sign s</w>
e p</w>
cycl in</w>
concentr ation
b en
pharmac okine
cyto kine</w>
ar com
ch ed</w>
n or</w>
mi str
main ly</w>
ev id
p ren
D R
B ,</w>
volum e</w>
apopto sis,</w>
al s,</w>
adi p
nit ros
loc al</w>
ur ac
ac a
en .</w>
memor y</w>
dens ity</w>
S i
D e
l a
mechanis m
re .</w>
bet ter</w>
haloperid ol</w>
d n
s ex
R T
P er
profil e</w>
pop ulation</w>
abnormal ities</w>
Q u
iso proteren
ro lim
met allo
adren ocept
D D
ud ed</w>
ome tr
es c
og r
anc es</w>
CYP1A 1</w>
Bcl -2</w>
am pl
act ing</w>
descri be</w>
4 ,
wom an</w>
prostagland in</w>
pot assi
ent ly,</w>
casp ase</w>
azep ine</w>
yl -
vi r</w>
trans form
si der
rele vant</w>
inter sti
al b
platel et</w>
th resh
sup pres
ap am
MM P-
6 %</w>
rec tal</w>
C ,</w>
RP O
val pro
PU RPO
c ou
bl ast
uc id
toge ther,</w>
inter actions</w>
block ade</w>
pos ed</w>
Bec ause</w>
ne w
di g
r he
r are</w>
assa ys</w>
A T</w>
im pac
es s,</w>
st abil
ol ar</w>
oc on
mark er</w>
ul f
C d
h .</w>
p ap
co ag
B )</w>
bl ot
3 9
t ox
l -
Ad di
on al</w>
affin ity</w>
wor k</w>
G )</w>
te tr
PURPO SE:</w>
ex ist
am ine-induced</w>
parti ally</w>
experim ents</w>
analys es</w>
deg ree</w>
metast atic</w>
mar ro
h ap
ag e.</w>
2 7</w>
de pression</w>
month s.</w>
hepat ocellular</w>
Ah R</w>
ra m</w>
pancre atic</w>
tyros ine</w>
fem al
epilep tic</w>
U n
3 1</w>
mod ynamic</w>
cur cum
19 9
ati c
prob ably</w>
occ ur</w>
R 1</w>
y me
aper itone
gas tro
r il
ac c
ri st
requ i
potenti ally</w>
ep t</w>
L i
id es</w>
deriv ati
maxim um</w>
know n.</w>
re li
metabol ite</w>
progester one</w>
D N
S ,</w>
pepti de</w>
p ut
j unc
carb am
phen ol</w>
cap ac
assa y.</w>
tri als</w>
cor tico
( 9
ag ed</w>
ab normal</w>
cl ass</w>
aldehy de</w>
al ap
th ir
00 0</w>
rec ip
en ,</w>
disorder s</w>
are a</w>
aden ocarcin
M .</w>
pl ant</w>
manif est
b asis</w>
ad duc
biom ar
an emia</w>
M RP
( K
su stained</w>
spont aneous</w>
h ,</w>
ed ed</w>
ograph ic</w>
effec tiv
ocic ep
el ucid
reg imen
revie w</w>
intersti tial</w>
common ly</w>
dop aminergic</w>
anti psych
bene ficial</w>
patter n</w>
3 7
analy sis.</w>
S ub
D uring</w>
vari ant</w>
particul arly</w>
aden osine</w>
y )</w>
u ter
complic ations</w>
conf idence</w>
gluc uron
1 1
eli or
condi tions</w>
al ter</w>
ische mic</w>
con sum
-2 ,</w>
-1 .
reg ar
V -
protein ,</w>
aut ophag
effect s,</w>
treat ments</w>
test o
degrad ation</w>
T GF-
t el
ogene sis.</w>
activ ator</w>
ic s</w>
d )</w>
T ak
V )</w>
ol -
an ,</w>
regul ate</w>
occur rence</w>
immuno hist
se em
cyste ine</w>
lit tle</w>
dist inc
50 %</w>
co hor
A p
otoxic ity.</w>
ni qu
mod ulation</w>
me tr
p to
pro gn
it er
grow th
er b
di hydro
diagnos ed</w>
0. 5</w>
re fract
Parkinson 's</w>
fail ed</w>
f ol</w>
I V</w>
tw ice</w>
an xi
( 95%</w>
exer cis
vas cul
t ure</w>
main ten
andro gen</w>
ri pt
o w
continu ous</w>
repa ir</w>
as ed</w>
L /
fi b
D 1</w>
av age</w>
anc e,</w>
te trac
O )</w>
2 2</w>
feat ures</w>
develop ing</w>
4 %</w>
outcom e</w>
s ity</w>
) /
test s</w>
rel ap
4 7
vi ability</w>
anim als.</w>
P L
An ti
5 6
H IF
sit es</w>
fe rence</w>
L e
om otor</w>
block ing</w>
rap id
perc ent
membr an
0. 9
ed ing</w>
e red</w>
dist ur
s le
matri x</w>
al ization</w>
repe ated</w>
pea k</w>
func tion,</w>
drug .</w>
1/ 2</w>
Effec t</w>
transpor ter
as e
3 7</w>
ca ffe
Tak en</w>
suc cess
ap pe
al- time</w>
H E
an ese</w>
there fore</w>
str ong</w>
iz ed,</w>
d on
cult ure</w>
activ ate</w>
W ist
T C
4 .</w>
f etal</w>
chol in
tri but
s core</w>
intr aperitone
dog s</w>
up- regulation</w>
am elior
M y
sec re
impac t</w>
high est</w>
di min
regul ating</w>
opi oid</w>
oche mistr
ec tion</w>
Th ree</w>
P B
= 0.0
ser ious</w>
func tions</w>
convuls ant</w>
elev ation</w>
carcin ogen
. 00
cor respon
A MP
cor ding</w>
impro ve</w>
initi ation</w>
progres sive</w>
microgram s/
al le
H um
0.00 1).</w>
prev al
i or</w>
diseas e,</w>
che m
au tis
adju st
achi eved</w>
lead s</w>
l ,</w>
hyp ox
AI D
3 2</w>
ob ut
under go
ri ght</w>
pregn anc
oxid ase</w>
lim ited</w>
ag ing</w>
oxygen ase-
my c
S P
M G
vis ual</w>
es s.</w>
K )</w>
ud ine</w>
toler ance</w>
or b
del e
ag e-
ol ig
S ince</w>
M n
si ze</w>
neut roph
n s</w>
ab dom
the tic</w>
re combin
at e-
2 8
pro xim
re comm
selec ted</w>
mat er
(+ )</w>
es tive</w>
abol ished</w>
2. 5</w>
( 8
rel atively</w>
lig and</w>
al ity</w>
cytokin es</w>
amin o</w>
A mon
activ ating</w>
lid ocaine</w>
acetyl chol
l ong</w>
Inhib ition</w>
wh ere</w>
l act
devel op</w>
(2+ )</w>
vir us</w>
trans l
diet ary</w>
as tro
frequ ent</w>
concomit ant</w>
MAP K</w>
ju g
follow- up</w>
b rom
anti bodi
a im
U T
system .</w>
ede ma</w>
gluc os
S OD
possi bly</w>
in si
w ent</w>
is ed</w>
7 ,
paclitax el</w>
fl ox
enc ing</w>
H L
Amon g</w>
refract ory</w>
gener al</w>
end oc
o rectal</w>
e m</w>
C .</w>
BP A</w>
6 5</w>
monit oring</w>
mon th</w>
fe w</w>
random ly</w>
p estic
mat ure</w>
lab el
se d
is e</w>
injec tions</w>
azep am</w>
st aining</w>
indometh acin</w>
2 6</w>
response .</w>
au g
i o
ext ent</w>
ari ly</w>
alb um
O R</w>
te en</w>
os in</w>
D I
mainten ance</w>
surfac e</w>
s .
N- acetyl
un treated</w>
potassi um</w>
gly co
0.0 1).</w>
P M
upreg ulation</w>
muc os
inte gr
glomer ul
compar able</w>
SO D</w>
doc um
6 0
organ ic</w>
de ,</w>
proc ess</w>
c ed</w>
ic ill
invol ving</w>
d in
ather oscler
pre dn
fluoro urac
double-bl ind</w>
se g
recei ve</w>
avail able</w>
7 2</w>
marro w</w>
Tw ent
de gener
collag en</w>
g al
g a
Res veratrol</w>
50 0</w>
f as
X R</w>
N P</w>
iti es.</w>
dexamethas one</w>
9 )</w>
oph il
at tribut
l ys
gluc ocortico
drug -
cl es</w>
it ation</w>
d o</w>
anti cancer</w>
7 5</w>
ment ed</w>
immun os
regi men</w>
r ic
si mul
le sion
o side</w>
de signed</w>
s ince</w>
down- regulation</w>
divid ed</w>
applic ation</w>
tech niqu
( II
os in
n g/m
discontinu ation</w>
ana esthe
ST AT
medic ation</w>
damag e.</w>
col orectal</w>
cl os
ren e</w>
oxid ation</w>
H ere</w>
l eng
ol y
meth od</w>
gen e.</w>
manag ement</w>
P E
(-1 )</w>
me d
perox is
oplas tic</w>
thyro id</w>
objec tive</w>
cell -
am ine,</w>
/ -
on ce</w>
h ome
g er</w>
dela yed</w>
pres cri
nife dipine</w>
aor tic</w>
en alap
F in
carb on
C linical</w>
ver apam
ri b
day )</w>
serot onin</w>
differenti al</w>
ap pl
ethan ol</w>
Hum an</w>
under went</w>
all -
can did
arra y</w>
recombin ant</w>
per fusion</w>
h our</w>
da il
as ,</w>
(2 .
tre at</w>
- activated</w>
ox et
enz yme
4 5</w>
l ic
propo fol</w>
ific ation</w>
In ter
3 5</w>
wil l</w>
mam mal
M -
I ,</w>
ul ative</w>
n ine</w>
gen es,</w>
en si
ex am
undergo ing</w>
foc al</w>
throu gh
op r
b re
well -
ind ,</w>
en al</w>
( m
v inc
tem por
provid es</w>
ti l</w>
er mal</w>
distri bution</w>
dehydrogen ase</w>
vas odi
rhe um
pro phyl
rec ent</w>
ne on
ic ,</w>
cir cul
L .</w>
meth yl</w>
f av
Sim il
neuro toxicity</w>
pre domin
3 6</w>
flav on
at s</w>
mer cur
mann er</w>
des pite</w>
activ ation,</w>
expres sions</w>
dismut ase</w>
sep ar
ax is</w>
am e</w>
vari ety</w>
micro mol/
meth od
id om
clear ance</w>
I g
regres sion</w>
enc es</w>
proxim al</w>
placeb o-
N B
propran olol</w>
pro por
chang ed</w>
occur ring</w>
micro g/
pro ble
ol amine</w>
occur s</w>
anti hypertensive</w>
u tive</w>
to -
re fle
syn ap
H i
spec tr
oplas mic</w>
ab in
VE GF</w>
not ed</w>
enhanc es</w>
cyclophosph amide</w>
sti t
re al-time</w>
Q T</w>
minut es</w>
fac il
con sider
IL- 6</w>
( ER
us e.</w>
l uc
appro ach</w>
micro M)</w>
di ure
cros s-
P revi
chi atric</w>
aver age</w>
acid ,</w>
TNF- alpha</w>
7 0
4 8
or ally</w>
l ec
pla yed</w>
alph a,</w>
HO -1</w>
sel en
D .</w>
stand ing</w>
rat e,</w>
U C
B y</w>
o in
es sive</w>
anti depress
adhe sion</w>
sen se</w>
opath y.</w>
lun g
GS H</w>
% ;</w>
antagonist ,</w>
recur rent</w>
con jug
compoun d
MD A</w>
res veratro
otrop ic</w>
ent am
an ine</w>
al one.</w>
Z n
Wist ar</w>
OBJECTIVE S:</w>
7 %</w>
-1 0
pa ren
gamma -
cal c
7 )</w>
post operative</w>
nucle otide</w>
cl assi
s che
os por
labor atory</w>
k erat
de .</w>
ant ,</w>
substr ate</w>
peri od.</w>
r in</w>
ol s</w>
hippocamp al</w>
NA S
u es</w>
re p
dr in
( mean</w>
lam iv
inf iltr
Ex pression</w>
rapid ly</w>
human s.</w>
ac tin</w>
ac r
nat ural</w>
ER K</w>
sel f-
ob last
vir al</w>
pheny to
p .</w>
defin ed</w>
t able</w>
drug -induced</w>
( 5</w>
main tained</w>
c ent
inter ac
G 1</w>
requ ir
D 2</w>
AI M
transloc ation</w>
rol es</w>
encod ing</w>
dom ain</w>
ch o
T RA
sco res</w>
examin ation</w>
mag ne
es ophag
distur b
P P
vol un
da ys
CYP3A 4</w>
pur pose</w>
m ary</w>
i.v .</w>
gen es.</w>
es )</w>
ac coun
Ne uro
par kinson
re stric
con sec
at tac
toler ated</w>
ab o
muc h</w>
las t</w>
distinc t</w>
C r
migr ation</w>
maxim al</w>
intr a
h el
lat er</w>
enh ance</w>
cholin ergic</w>
b ound</w>
al k
B e
med ical</w>
chemo therapeutic</w>
1 2-
s w
home ost
fr action</w>
ar yl</w>
C y
olog ically</w>
mit ted</w>
pot ency</w>
inhib i
appe ar</w>
func tion
p s</w>
z ol
em ia,</w>
con ven
CYP2 A
hydro carbon</w>
di z
na use
lif e</w>
in a</w>
diseas es</w>
IL- 8</w>
Fin ally,</w>
assess ment</w>
3 8
ve di
ine ster
r ho
prev ent
youn g</w>
cer tain</w>
toge ther</w>
proc ed
m u
el etal</w>
smo oth</w>
le y</w>
ic ro
er gen
effec tively</w>
tri glycer
phenotyp e</w>
agent s.</w>
perform ance</w>
low ing</w>
epilep tic
ec al</w>
auth ors</w>
pro toc
k .</w>
ide -induced</w>
am ine.</w>
nucle us</w>
as ts</w>
hist one</w>
( PA
c ann
C u
m urine</w>
hepat ocytes</w>
complic ation</w>
(n =
hyperalge sia</w>
cum ulative</w>
(2 -
9 %</w>
s in</w>
neuro lep
carri ed</w>
C ardi
po or</w>
oxygen ase</w>
I -
A ),</w>
( RO
yl )
head ach
ev oked</w>
infec tion</w>
i ve</w>
e :</w>
3 /
show s</w>
capsa icin</w>
acid s</w>
M et
C X
vedi lol</w>
ac cording</w>
per me
dos e.</w>
d es</w>
Im mun
capac ity</w>
T P
methotrex ate</w>
concl uded</w>
NP s</w>
side -
pressu re,</w>
risperid one</w>
C G
10 -
y :</w>
lac k</w>
Tran s
0. 8
ment ,</w>
X R
5- fluorourac
m as
a ph
In te
0. 5
y si
ophyl line</w>
b ul
0. 6
3 00</w>
glutam ate</w>
cor tis
PI 3
l ine
an other</w>
pathwa ys.</w>
cat ech
behavi or</w>
ant .</w>
( W
w ho
tre m
g est
D ,</w>
te x</w>
struct ural</w>
rolim us</w>
ro d
ab ine</w>
p 2
one -induced</w>
identi fi
ent s.</w>
T r
Fur ther</w>
C F
y s,</w>
p al
un known.</w>
si g
cor tical</w>
piv aca
no rep
hypertroph y</w>
cr iter
tum ors.</w>
pre treated</w>
9 0
10 0
conver ting</w>
P F
D es
stres s.</w>
recept ors.</w>
persist ent</w>
op a
mat ched</w>
inc id
gene sis</w>
protein .</w>
os ome</w>
arrhyth mic</w>
anesthe sia</w>
2 5-
i es,</w>
down stream</w>
p an
modi fied</w>
affec ting</w>
DE SIGN
ser ies</w>
he mo
b ic
abo ve</w>
inter val
alco hol</w>
U NAS
UNAS SIGN
UNASSIGN E
Res ul
ures ,</w>
testo sterone</w>
ation -
UNASSIGNE D:</w>
double-bl ind,</w>
cult ures</w>
5-F U</w>
tri oxide</w>
neurolog ical</w>
fi el
consec utive</w>
anti body</w>
alco h
inter ven
M ),</w>
2 4-
id s</w>
jec tion</w>
n ul
compar e</w>
protein uria</w>
percent age</w>
hum ans</w>
epith eli
air way</w>
ER I
C E
ech ocardi
altern ative</w>
stro ke</w>
produc ts</w>
prev ents</w>
up- regulated</w>
in suffici
b ,</w>
ant s.</w>
CA M
od ds</w>
( 100</w>
volun te
or ig
b ar
U D
ti le</w>
t a</w>
M R
pa thetic</w>
biop sy</w>
rec ru
random ized,</w>
X -
v an
rheum at
op re
im id
el der
a sis.</w>
3 ).</w>
deple tion</w>
uc t
ma .</w>
ven ous</w>
ra ther</w>
0.00 1)</w>
om ycin</w>
enc e,</w>
comp eti
re ly</w>
melan oma</w>
ffe red</w>
] ,</w>
Th e
2 50</w>
ret ur
l otyp
cor tex</w>
O r
un til</w>
compon ent</w>
A 1</w>
mi gra
contribut es</w>
characteris tics</w>
In tr
g entam
M I
observ ations</w>
mam mary</w>
l ing</w>
ect om
seiz ures.</w>
includ e</w>
group s,</w>
ac erb
om i
amiodar one</w>
Thi r
S pr
A A</w>
treat ing</w>
lo ad
-1 .</w>
v om
d ri
heal th</w>
flur ane</w>
catalep sy</w>
underst o
til ity</w>
low- dose</w>
unc lear
em p
tum ori
sur g
psy chiatric</w>
incub ation</w>
be g
overex press
diseas es.</w>
da y,</w>
agg reg
DESIGN :</w>
Ch in
tum or
prolifer ation,</w>
mit ogen
mammal ian</w>
sche dul
enc ies</w>
re fl
seem s</w>
ac qu
A m
vinc rist
studi ed.</w>
pre par
perc ent</w>
os yn
U V
Ser um</w>
(- /-
surger y</w>
promis ing</w>
pilocar p
ne ed</w>
ische mia</w>
in take</w>
tum our</w>
curcum in</w>
catal y
th ym
who m</w>
meth oxy
s qu
rest ingly,</w>
rel ation</w>
on co
at ri
Resul ts</w>
7 7
ut ed</w>
region s</w>
pu t</w>
om orph
investig ated.</w>
in tro
ha ving</w>
al kal
gen e,</w>
e al</w>
on ,</w>
facil it
er -
en sive</w>
de n</w>
anti tumor</w>
an o
Nrf 2</w>
H ER
s ligh
el imin
peroxid ation</w>
mi a.</w>
RT- PCR</w>
2 9</w>
p ig
flu id</w>
T NF
trans plant</w>
toxic ity,</w>
subun it</w>
peroxis ome</w>
el em
L N
le th
hist opath
o w</w>
cor rec
at ,</w>
appl ied</w>
D aw
con cer
al ong</w>
Hy per
ur ic</w>
pen icill
4 5
the m</w>
he par
F ol
upreg ulated</w>
sim vastatin</w>
ro x
ol ytic</w>
long er</w>
it ary</w>
import ance</w>
ir ub
P las
C ol
sh ock</w>
myc in</w>
he mol
2, 3,
chemo therapy.</w>
i.p. )</w>
Spr ag
P ,</w>
6 .</w>
steroid al</w>
sing le-
rheumat oid</w>
respectively ).</w>
literat ure</w>
genotyp es</w>
Ex pos
R F
JN K</w>
A F
si vely</w>
[ a
l ate</w>
ear ch</w>
condi tion
bu pivaca
acet ate</w>
ac ch
u e-
repor ted.</w>
fibrill ation</w>
abs or
S E</w>
st -
molecul es</w>
child ren
Ca 2
tic ul
il e</w>
di p
vehic le</w>
s ca
ini b</w>
brady cardia</w>
Daw ley</w>
enc e.</w>
H T</w>
typ ical</w>
simul t
id ity</w>
en rol
stri atal</w>
bron chi
P D</w>
A /
7, 8-
develop mental</w>
as al</w>
SI RT
targ ets</w>
A b
1 A</w>
0.0 1)</w>
thresh old</w>
recor ded</w>
investig ation</w>
d g
cyt ometr
T ,</w>
D A</w>
D is
ex acerb
endome trial</w>
cap top
agg res
sin us</w>
op tim
all ,</w>
ul tr
curren tly</w>
conven tional</w>
pa in.</w>
d en
candid ate</w>
down regulation</w>
si a,</w>
cat en
al g
Inte restingly,</w>
go od</w>
continu ed</w>
benz ene</w>
IF N-
H ]
in es</w>
W hile</w>
U /
inf ected</w>
indic ates</w>
A G
re main</w>
prim arily</w>
preval ence</w>
amoun t</w>
aim ed</w>
in toxic
drin king</w>
block er</w>
oph ysi
necess ary</w>
hospit al</w>
correspon ding</w>
M ).</w>
te d,</w>
prevent ing</w>
dis played</w>
ad ri
CI ,</w>
gr af
clo zapine</w>
synthe tic</w>
fol ate</w>
cycl ic</w>
antibodi es</w>
pu bl
es tion</w>
endoc rine</w>
coll ected</w>
u ally</w>
thir d</w>
protec ts</w>
loc omotor</w>
pro spective</w>
di methyl
b el
e osin
pr on
com pl
( 4-
subjec ts.</w>
N K
sy .</w>
m ang
l ine,</w>
h ere</w>
adrenocept or</w>
adju vant</w>
P PA
AT P</w>
AM P</w>
ro si
m ade</w>
estim ated</w>
cohor t</w>
ath ecal</w>
andro gen
macroph ages</w>
i ary</w>
struct ure</w>
p as
car r
st er</w>
protec t</w>
om en
modul ate</w>
ch arg
year s.</w>
lev od
clon idine</w>
c .
appro pri
y et</w>
ol ip
level .</w>
ine- treated</w>
asth ma</w>
W ith</w>
test ing</w>
ro g
os fam
hypothe sized</w>
gener ated</w>
H )</w>
si ven
episod es</w>
all ergic</w>
Com par
inten sity</w>
exercis e</w>
drug s,</w>
analge sic</w>
tic s.</w>
ne i
in a
1B 1</w>
s '</w>
g em
de generation</w>
possi bility</w>
nal ox
h er</w>
ti s,</w>
nul l</w>
mg/ d
hap lotyp
fi t</w>
er ous</w>
amy cin
L R
A Z
n ed</w>
ic ity</w>
gastro intestinal</w>
ti li
respon s
r hyth
ocyt es,</w>
fibrobl asts</w>
canc er,</w>
b ur
ar rest
re present</w>
re plic
re mo
Expos ure</w>
opre ven
amid al</w>
3 3
0. 7
( AT
po ison
day s,</w>
4 3</w>
through out</w>
stri at
tw o-
synerg istic</w>
on es</w>
medi ates</w>
hypoten sive</w>
1. 0
studi es.</w>
rat .</w>
time -dependent</w>
pres ents</w>
kerat in
ac u
1. 5</w>
st op
o sis,</w>
K /
5 ).</w>
ne ural</w>
Twent y-
E E
- binding</w>
hyper pla
arrhythmi as</w>
s o</w>
O ver
sh e</w>
produc t</w>
pos s
ca using</w>
sens ory</w>
he modynamic</w>
el y,</w>
cy sti
NF-k B</w>
op ic</w>
0. 1</w>
P S
tion -
sol ub
ha em
epid ermal</w>
B R
ve ,</w>
towar d</w>
B 1</w>
transplant ation</w>
fluoresc ence</w>
flu oxet
trans -
if amp
medi um</w>
find ing</w>
d yst
S ign
D 3</w>
C A</w>
con g
appa rent</w>
m T
exc ept</w>
elic ited</w>
Ch ron
unclear .</w>
o tri
nephro toxicity</w>
5 ,
vi e
Se ver
E NT
ogr af
inester ase</w>
B .</w>
3 6
in os
gener ally</w>
con sc
H ist
tion ally,</w>
in formation</w>
dr am
radi o
carcin ogenesis</w>
cal cul
bac ter
St ud
prote as
( e
we ak
ifer ase</w>
cad mium</w>
HB V</w>
Des pite</w>
5 .</w>
sligh tly</w>
ocyt open
P -1</w>
week s,</w>
es :</w>
poin t
detec tion</w>
ar d
pla in</w>
ch est</w>
usu ally</w>
trans genic</w>
stres s,</w>
spec tro
or th
eff lu
Sprag ue-
3 8</w>
consum ption</w>
Q T
F our</w>
mitogen -activated</w>
metallo protein
k er</w>
arsen ic
A C</w>
wh ose</w>
patient 's</w>
o ther
convul sions</w>
l ine.</w>
l )</w>
cardiomy opathy</w>
anti gen</w>
Inc reased</w>
studi es,</w>
sle ep</w>
ill ary</w>
effectiv en
a k</w>
- 3</w>
caffe ine</w>
blast oma</w>
on .</w>
i a
e f</w>
cl ar
cas es.</w>
at or-
us ers</w>
ox yl
M MP
specific ally</w>
ris e</w>
monit ored</w>
arth ritis</w>
MT X</w>
spectr um</w>
hist ological</w>
Ad mini
shor t</w>
profil es</w>
phosph ati
fe ren
chro mat
car e</w>
leng th</w>
gu an
de d.</w>
ap yr
T RP
(I L
wh ite</w>
lo fen
iv al
HIF -1
te tra
Plas ma</w>
P r
re ticul
n an
hepat otoxicity</w>
phen obarb
et er</w>
dimin ished</w>
Sprague- Dawley</w>
phen omen
on ate</w>
chem opreven
analy sis,</w>
ub iqu
sym pathetic</w>
quin one</w>
g re
z ot
malign anc
idom ide</w>
al do
Pre treatment</w>
J ap
target ing</w>
k ,</w>
cel er
ab b
P <
or ity</w>
ba vir
The y</w>
D ru
Chron ic</w>
(4 )</w>
nephro tic</w>
nei ther</w>
mater nal</w>
ligand s</w>
oc clu
mg/m 2</w>
ent s,</w>
cycl ospor
I T
mechan ical</w>
inf ants</w>
vari ation</w>
A P</w>
3 ),</w>
tiv e,</w>
provid ed</w>
duc ed</w>
di ed</w>
channel s</w>
erg y</w>
er r
clin ic
un g
dys function.</w>
arcom a</w>
strateg y</w>
revie w
coca ine-
al ve
G C
spont aneously</w>
e y
control .</w>
al most</w>
D el
is ,</w>
4 6
deg re
carcin ogenic</w>
affec ts</w>
accum ul
VE GF
UGT 1A
g all
coun ter
at onin</w>
E D
Ar sen
sub stitu
rel ax
M A</w>
pron oun
phosphat ase</w>
molecul e</w>
immunos up
[a ]
I NT
ol an
hyper activity</w>
h and,</w>
electro cardi
show ing</w>
path ophysi
im aging</w>
EGF R</w>
sequenc es</w>
knock down</w>
activ ates</w>
supple mentation</w>
depend ence</w>
incub ated</w>
th re
surg ical</w>
sca ven
cir rho
op l
b ic</w>
synap tic</w>
path ological</w>
c y</w>
R ats</w>
z af
derivati ves</w>
E i
O x
pilocar pine</w>
met al</w>
em ergen
AC E</w>
tr yp
ad ded</w>
Admini str
(A B
( i.
ob es
fr ac
f atal</w>
capsa ic
ath ion
as signed</w>
xen ograf
l .</w>
car vedilol</w>
ocicep tive</w>
diff er</w>
T B
produc tion.</w>
or ation</w>
headach e</w>
hom ozygous</w>
amin oph
Addi tionally,</w>
- specific</w>
(-/- )</w>
R enal</w>
M AT
G L
thal am
symptom s.</w>
nephropath y</w>
mi R
l ation</w>
cyt es</w>
ac celer
A 54
enalap ril</w>
detec table</w>
aminoph en</w>
5 %)</w>
appear ance</w>
(50 )</w>
saf e</w>
minim al</w>
inva sive</w>
ev ent</w>
cop per
E D</w>
ve si
os yl
ant s,</w>
SH -
Rec ent</w>
2 A</w>
sk eletal</w>
elder ly</w>
ph ot
esophag eal</w>
decreas ing</w>
chemic als</w>
c- J
(A D
(+ )-
process es</w>
patter ns</w>
mut ag
di oxin</w>
10 ,</w>
scre ening</w>
g raph
f at</w>
concentration -dependent</w>
Ac tiv
im medi
electro ph
cardi otoxicity</w>
Ba x</w>
S ),</w>
1 5-
extrac t</w>
ent er
cle arly</w>
chrom osome</w>
catal ytic</w>
phosphoryl ated</w>
S p
Com pared</w>
luc iferase</w>
docum ented</w>
cor d</w>
bene fit</w>
3 3</w>
m mol/
Previ ous</w>
sulf ate</w>
stop p
rest ored</w>
n am
electro n</w>
prolifer ation.</w>
m im
in activation</w>
- regulated</w>
year s,</w>
org an</w>
G E
B i
ma z
ine )</w>
CYP2 D
5-F U
us t</w>
dele tion</w>
steroid s</w>
radi ation</w>
confir m</w>
promot e</w>
low ering</w>
assa y,</w>
4 2</w>
exp lo
P .</w>
M P</w>
xen ob
am ,</w>
adenocarcin oma</w>
G lu
( 2</w>
si RNA</w>
s cler
expos ure,</w>
enhanc ement</w>
con gen
b ell
om e-
ac ts</w>
N )</w>
E v
subsequ ently</w>
canc ers</w>
ant ly,</w>
A g
resist ance.</w>
protein s.</w>
f ron
appropri ate</w>
anth rac
under standing</w>
pronoun ced</w>
promot es</w>
prolifer ator-
he me</w>
hal oth
expl ore</w>
exc it
suscepti ble</w>
suppress or</w>
fac ial</w>
C ell</w>
v in
ul in</w>
ti az
symptom atic</w>
recip i
ne eded</w>
il lin
hypox ia</w>
f ore
arrhyth mia</w>
Di fferen
A L</w>
4 4</w>
( h
down- regulated</w>
d yl
condi tion</w>
arth ri
Q O
9 9
star ting</w>
r abb
hloro di
el ement</w>
c et
per for
lipo protein</w>
cou pl
anesthe tized</w>
M ut
C /
- associated</w>
sub cutaneous</w>
catal ase</w>
ta il
metabolis m.</w>
effectiven ess</w>
there by</w>
suppres s</w>
prol act
meas ures</w>
de qu
cong estive</w>
shor t
intr athecal</w>
di atric</w>
concentr ations.</w>
in -1</w>
verapam il</w>
ve ments</w>
u n</w>
poin ts</w>
enc y.</w>
ag ic</w>
ri g
proliferator- activated</w>
fo od</w>
benz odi
M 1</w>
w er</w>
NF- kappa
G P
th at,</w>
inva sion</w>
anti convulsant</w>
R eg
ON :</w>
Chin ese</w>
An g
s al</w>
mg/ day</w>
attenu ates</w>
appro ach
le dg
N MDA</w>
- -
understo od.</w>
protein s,</w>
ure a</w>
lin es,</w>
con st
compon ents</w>
cas es,</w>
attribut ed</w>
thi az
f il
con struc
. g
un iqu
tre n
pro posed</w>
estro genic</w>
er 's</w>
end -
y ;</w>
mechanis m.</w>
iti es,</w>
at es.</w>
am ine-
B lo
4 00</w>
ochemistr y</w>
o ro
me to
demonstr ates</w>
Administr ation</w>
signific ance</w>
r ifamp
prof en</w>
po or
immun ore
produc es</w>
Sever al</w>
NA DP
E L
ti dine</w>
defec ts</w>
MA P</w>
phenyto in</w>
ex plain</w>
c DNA</w>
at ur
regul ator</w>
n ar
meth amphetamine</w>
kin ases</w>
drug ,</w>
Com bin
equ al</w>
develop ment.</w>
der s</w>
target ed</w>
sensi tiv
pathwa y,</w>
month s,</w>
associ ations</w>
ab und
nitro glycer
hist amine</w>
hi s</w>
coag ul
arac h
am ne
all y.</w>
ve .</w>
the ophylline</w>
res er
re ach
r in
myel oma</w>
antipsych otic</w>
4 /
-1 0</w>
long -
isoproteren ol</w>
(2 0</w>
sp as
re mission</w>
ph thal
mitochondri a</w>
col on
tachy cardi
k ill
condi tions.</w>
bec ame</w>
ad ol
M ul
' ,
thou ght</w>
present ing</w>
epilep sy</w>
d obut
K ,</w>
CY P</w>
As 2O
ym ptom
week ly</w>
hear ing</w>
he at</w>
embry onic</w>
dos ing</w>
disorder s.</w>
P4 50
trans formation</w>
di ethyl
I GF
4 9
ri bavir
refle x</w>
rat e.</w>
pr ac
meas ure</w>
form ed</w>
flox acin</w>
fiel d</w>
at a</w>
4 ).</w>
sp ir
rad ical</w>
model s.</w>
re -
norep inephrine</w>
ear li
P ON
A PA
(p <
iti s.</w>
arsen ite</w>
an .</w>
( 50</w>
respon siven
n ex
H .</w>
ys acch
tri al.</w>
popul ation.</w>
mechanism s.</w>
ma ,</w>
i )</w>
carcin omas</w>
P ATI
H L-
atic ally</w>
1 50</w>
dos e,</w>
autophag y</w>
t in
initi ated</w>
potenti ated</w>
ob struc
no w</w>
expres s</w>
en ic</w>
val id
oc ular</w>
know ledg
encephal opathy</w>
adren aline</w>
receptor .</w>
fo ur
emp lo
S cal
E p
v es
hy bri
gen omic</w>
T H</w>
los artan</w>
exhib it</w>
ed -
ar ,</w>
(M AP
( a</w>
sc ale</w>
p5 3-
o g</w>
exp ected</w>
exer t</w>
en ia</w>
cl op
as part
5-fluorourac il</w>
( RA
v ag
si s-
reduc tions</w>
lymph oma</w>
form ation.</w>
defic its</w>
cle avage</w>
av oid
E ,</w>
thromb ocytopen
shi ft</w>
pr us
pit u
phosph olip
neon atal</w>
im plant
protec ted</w>
onucle ar</w>
observ ation</w>
M E</w>
implic ations</w>
tempor al</w>
t oxin</w>
neutroph il
if osfam
S Y
olog y.</w>
lim iting</w>
I P</w>
I .</w>
G ,</w>
C ur
- derived</w>
f ying</w>
S -induced</w>
PATI ENT
C or
mus cular</w>
g ang
b ir
suppress es</w>
su spec
liver .</w>
ic an</w>
h r</w>
F L
-1 ,
ultr as
rec ove
ad mitted</w>
2 2
H P
F 1</w>
ur ally</w>
res earch</w>
insul in-
circul ating</w>
a reas</w>
s or
at yp
S NPs</w>
placeb o.</w>
hippocamp us</w>
abil ity,</w>
[ 3
qu ine</w>
pol ar</w>
lo we
inos it
discus sed.</w>
biomar kers</w>
tic s,</w>
op ol
bi osyn
MMP- 9</w>
F GF
in sic</w>
d yn
trigg ered</w>
solub le</w>
regar ding</w>
receptor s,</w>
meth ad
differenti ally</w>
apyr amidal</w>
Blo od</w>
un d</w>
transcri pt
stimul ating</w>
mem b
i az
ho w</w>
ex clu
b )</w>
squ am
m M</w>
ste re
model ,</w>
exam ined.</w>
efflu x</w>
am ide,</w>
bar ri
PPAR gamma</w>
N or
ser ved</w>
predn isol
ocy cl
lear ning</w>
exten sive</w>
respec t</w>
competi tive</w>
AT RA</w>
A54 9</w>
mal es</w>
alter ation</w>
3 4</w>
ret inal</w>
put ative</w>
o t</w>
he im
c u
ac ro
Ca (2+)</w>
macroph age</w>
invol ves</w>
injec tion.</w>
glob al</w>
ex ogenous</w>
differenti ated</w>
ac tic</w>
coca ine-induced</w>
cann abin
S he</w>
M S</w>
ros s</w>
re press
resol ved</w>
interleukin -
benz o-
O H-
ve in</w>
u tili
pp m</w>
ocy to
administr ation,</w>
ab use</w>
on s</w>
me dul
ch ym
Sign ific
N R
MD A-
A A
trans mission</w>
pro inflammatory</w>
lat eral</w>
dis co
degre es</w>
cr uc
Al z
recogn ized</w>
per oxide</w>
ox im
opo i
amin es</w>
alve olar</w>
top ical</w>
lamiv udine</w>
ide mi
h am
dis charg
d y
le ph
fact ors.</w>
app a</w>
ap omorph
Ph armac
C 1</w>
(RO S)</w>
( AC
ren in</w>
opol ysacch
ne um
mm Hg
es ;</w>
adjust ed</w>
1. 0</w>
pressu re.</w>
e tin</w>
da y.</w>
ATP ase</w>
ro ten
ome tric</w>
myel oid</w>
block ers</w>
patient .</w>
myel ocytic</w>
mm Hg</w>
lo id</w>
ket amine</w>
On ly</w>
si c
level ,</w>
5 3</w>
opath ic</w>
immedi ately</w>
detec t</w>
ad dic
phosphati dyl
ch el
caten in</w>
an ter
I V
Fol lowing</w>
Alz heim
gener alized</w>
ad ine</w>
acet aminophen</w>
uniqu e</w>
recomm ended</w>
neuro blastoma</w>
i ste
hyperten sion,</w>
time ,</w>
se m
elucid ate</w>
alpha )</w>
ag es.</w>
ubiqu it
thromb osis</w>
t or</w>
raz ole</w>
fentan yl</w>
ant in
ab rog
M L
H )
su peri
op en</w>
min ,</w>
CYP2C 9</w>
abil ity.</w>
multi drug</w>
ar ti
R B
R ),</w>
HC C</w>
bil ateral</w>
al anine</w>
M ost</w>
A D</w>
nitro prus
m l</w>
enzym atic</w>
e ve</w>
at en
M eth
prolong ation</w>
poor ly</w>
mon ke
dil tiaz
control s,</w>
min or</w>
et ax
prop yl
maj ority</w>
gem cit
di azepam</w>
cere bell
c re
benzo- p-
C 57
p recur
endoth el
squam ous</w>
pro lol</w>
pre dis
ol ine</w>
hydrox y-
f oun
model ing</w>
alk yl
pro gram
me tic</w>
ineph r
di pyrid
acid .</w>
ab err
( 0.0
predic ted</w>
glob in</w>
disrup tion</w>
ad ap
p um
mix ed</w>
i bu
domin ant</w>
(I C
(2 )-
smo king</w>
respectiv ely</w>
micro array</w>
eosin ophil
e jection</w>
cle ar</w>
PG E
soci ation</w>
rosi glitazone</w>
blo od
agent ,</w>
L- DO
st a
n ,</w>
mg/kg ),</w>
e .,</w>
wh ole</w>
interfer on</w>
i el
i NOS</w>
find ing
A mer
retur ned</w>
per son
arter i
Me an</w>
signal ing.</w>
rati os</w>
cas e-
u str
prescri bed</w>
lymph ocytes</w>
li ver,</w>
gli oma</w>
gang li
dipyrid am
degener ative</w>
LP S</w>
r as
determ ined.</w>
abdom inal</w>
3 %)</w>
n -
c AMP</w>
us al</w>
response ,</w>
placebo- controlled</w>
gli al</w>
bronchi al</w>
bil iary</w>
V PA</w>
tetra hydro
recur rence</w>
in ated</w>
ch ic
PC B
MAT ERI
oxi b</w>
il ,</w>
h aled</w>
dose- dependently</w>
ERK 1/2</w>
( CYP
sign all
it .</w>
in um</w>
at ure</w>
a emia</w>
AL S</w>
mel atonin</w>
ex on</w>
elec tr
e -</w>
atyp ical</w>
tac t</w>
s. c
re ad
man ner
loc ated</w>
equ ival
aspart ate</w>
acet am
N AT
microsom es</w>
micro g</w>
loc alization</w>
be st
E r
2,3, 7,8-
( 3</w>
tissu es.</w>
system s</w>
pro myelocytic</w>
he ad</w>
h ar
damag e,</w>
an -
4 1</w>
t ing.</w>
larg ely</w>
intraven ously</w>
hemorrh age</w>
ffic ul
epileptic us</w>
antagon ized</w>
yl ate</w>
promot ing</w>
ot er
experi ence</w>
cros s
challeng e</w>
(O H)
vari ability</w>
v enti
omer ase</w>
hepat oma</w>
auto immune</w>
B ased</w>
-2 )</w>
trac t</w>
sum mar
requi re
promot ed</w>
impro ves</w>
estrogen s</w>
oblas tic</w>
PA )</w>
Arsen ic</w>
yc lo
s es
ocy ste
e /
carbam azepine</w>
N G
D a
ACh E</w>
12 0</w>
intraperitone al</w>
ine /
ang ina</w>
C AT
me ans</w>
indometh ac
pro spec
p raz
on ia</w>
F .</w>
C M
-2 .
leuk in</w>
interfer ing</w>
glucocortico id</w>
cr an
0.05 ),</w>
um -induced</w>
transporter s</w>
t ab
carcin om
a rom
Pro te
( U
ou ab
mid azol
is ch
F ive</w>
mono therapy</w>
lip opolysacch
leth al</w>
if y</w>
identi fication</w>
exer ts</w>
ac ross</w>
I N</w>
1 2.
us es</w>
propor tion</w>
hyper sensitivity</w>
bol us</w>
B /
ve d,</w>
protein -
S ev
Bcl -
re ten
oxid ant</w>
inc or
ha e
f et
E .</w>
1 ;</w>
re presents</w>
ocon stric
di fficul
allel es</w>
R ep
As (2)O
A S</w>
recove red</w>
ol ysis</w>
lo t</w>
di am
3 9</w>
period ,</w>
out put</w>
canc ers.</w>
ad renal</w>
P oly
) :</w>
v ect
success fully</w>
mul tic
migra ine</w>
interv als</w>
f en</w>
co d
H e</w>
selec tively</w>
new ly</w>
enrol led</w>
atro ph
z e
mercur y</w>
l d</w>
fail ure,</w>
bupivaca ine</w>
olog y,</w>
ge l</w>
character istic</w>
C57 B
smo k
refl ec
pharmacokine tic</w>
neuro protective</w>
de acetyl
bre ak
M ale</w>
y iel
sw it
se .</w>
re produc
anti arrhythmic</w>
S ur
paclitax el
hyp oxi
hydro gen</w>
ER alpha</w>
vitro ,</w>
oblast oma</w>
ine mia</w>
di an</w>
oxi di
dyskine sia</w>
at tem
LN Ca
B M
surger y.</w>
endoth eli
end ing</w>
descri be
contri bution</w>
bene f
H ,</w>
D F
A 2</w>
s or</w>
or ,</w>
mg )</w>
th reat
sion al</w>
min .</w>
cyclo oxygenase-
E X
t /
se ud
schizophren ia</w>
receptor ,</w>
mo l</w>
measure ments</w>
l ut
hlorodi benzo-p-
e ;</w>
arg inine</w>
T S
t an
superi or</w>
rest ing</w>
1 0.
se ve
pregnanc y</w>
ma x
h all
h )</w>
glut athion
4 ),</w>
t ors
ro ut
f uro
criter ia</w>
analge sia</w>
am lo
5 9
(3 )
( group</w>
vari abl
in hal
c-J un</w>
vast at
discontinu ed</w>
depres sive</w>
transf ection</w>
st ain
rad ic
ox al
men ing
incor por
cess ation</w>
4 7</w>
short -term</w>
pheny leph
ep inephrine</w>
V D
tum our
t )</w>
produc ing</w>
H R
ve red</w>
ran ial</w>
le sion</w>
ec tin</w>
biosyn the
al azine</w>
C ac
1 1.
v ation</w>
sal t</w>
in tact</w>
hepat ocyte</w>
fir st-
do x</w>
cruc ial</w>
P O
s ph
pre mature</w>
off sp
iz ation.</w>
epi genetic</w>
[3 H]
NS AID
5 '-
partic ular</w>
og ram</w>
endome tri
e dr
L O
D S)</w>
An alysis</w>
tem per
t ex
sensitiz ation</w>
responsiven ess</w>
pres sive</w>
predomin antly</w>
inflamm ation.</w>
der mal</w>
a -induced</w>
N F</w>
st ability</w>
las tic</w>
d u
F e
qu es
phen yl</w>
o in</w>
norm ot
micro g/m
T 1</w>
I GF-
GAB A
ul t
se x</w>
or .</w>
ome- wide</w>
larg er</w>
coupl ed</w>
i b
d ors
LD L</w>
wor sen
ad d
CS F</w>
neurolog ic</w>
morph ological</w>
evalu ated.</w>
ti es</w>
t as
star ted</w>
neuron s.</w>
h und
control ,</w>
carri ers</w>
D ec
8 .</w>
ynam ics</w>
sc al
pa in,</w>
mg ,</w>
en ergy</w>
pa rox
conduc tion</w>
al one,</w>
F ,</w>
st ages</w>
sion s.</w>
regimen s</w>
inhibitor s.</w>
fer red</w>
acetylchol ine</w>
F or
spec imen
ste at
pres er
extr apyramidal</w>
5 5</w>
system ,</w>
place ment</w>
n M</w>
mus t</w>
knock out</w>
inhibitor s,</w>
ho od</w>
(3 .
stimul ate</w>
li qu
analy z
S NP</w>
tissu e.</w>
so ur
p neum
levod op
in n
hydroxyl ase</w>
heter ozygous</w>
bra in.</w>
agonist ,</w>
agent .</w>
quer cet
men opa
cere bro
ac tion.</w>
fron tal</w>
cytos olic</w>
ar ly,</w>
test .</w>
me d.</w>
inter leukin</w>
deter i
re dox</w>
m atic</w>
Rec ently,</w>
L ong
2 %)</w>
- resistant</w>
stre pto
pro m
predic t</w>
magne si
dyskine si
HL- 60</w>
thal idomide</w>
substr ates</w>
arom atic</w>
H yp
zot oc
tub er
oc ript
mus car
m s.</w>
it ro
i pr
effect ,</w>
HC T
w arr
modul ates</w>
glyco protein</w>
F K
CD K
infu sion.</w>
in ning</w>
a /
In duction</w>
GAB A</w>
(i )</w>
si z
physi cal</w>
doc etax
dic lofen
chemopreven tive</w>
ar m</w>
am .</w>
L V</w>
Ch ang
1 3.
ter ms</w>
s low</w>
rou s</w>
o m</w>
hydro l
ca th
yl chol
viv o,</w>
usu al</w>
up per</w>
trans duction</w>
al low
pilocarp ine-induced</w>
T X
NA D
ul cer
u tri
suffici ent</w>
ste ad
s per
l ess
f low
dou ble</w>
absor ption</w>
op yr
clos ely</w>
RT- PC
Jap anese</w>
subjec ted</w>
pe diatric</w>
last ing</w>
i le
bin d</w>
activ ities.</w>
TRP V
SY 5
w all</w>
sil encing</w>
op res
hemol ytic</w>
fluoxet ine</w>
captop ril</w>
bal ance</w>
P 1</w>
signal -regulated</w>
perme ability</w>
outcom es</w>
modi fication</w>
injur y,</w>
character ize</w>
am mon
adduc ts</w>
um erous</w>
p s
evid ent</w>
dos es.</w>
af ter
( 3-
Stud y</w>
SIRT 1</w>
C ar
B r
1 %)</w>
0. 2</w>
thi azol
rang e,</w>
peroxid ase</w>
mor b
ATP 7
AK R
sam ple</w>
s atur
reve al</w>
exist ing</w>
rever sal</w>
repor t.</w>
o- 2</w>
mucos al</w>
mem ber</w>
lat ter</w>
iz es</w>
album in</w>
remain ing</w>
r as</w>
medi ating</w>
lowe red</w>
0.0 5</w>
open -
inhibi tion.</w>
homeost asis</w>
4 '-
ul monary</w>
sex ual</w>
re mark
mag nit
loc alized</w>
ic -
f ung
expl ained</w>
down regulated</w>
bet a,</w>
al ol</w>
O ther</w>
0. 3</w>
modul ating</w>
h r
disorder .</w>
deriv ative</w>
ST R
= 0.00
sul ph
pharmacokine tics</w>
cont amin
n asal</w>
k g/
S- transferase</w>
(C OX
us ed.</w>
g ain</w>
diagnos tic</w>
angiotens in-
agent s,</w>
a e</w>
HS P
C C</w>
A ).</w>
( c
par aqu
my ocl
in )</w>
fibrobl ast
20 %</w>
19 8
medic ations</w>
l ot
te ste
serot on
le uc
anter ior</w>
mut ated</w>
inosit ol</w>
dic hloro
CYP2 E1</w>
su d
recru it
dist al</w>
alle l</w>
K 56
2 B
vas oconstric
su ff
retro spective</w>
properti es.</w>
attem p
5 2</w>
th ic
kg (-1)</w>
dequ ate</w>
chang es.</w>
ar ing</w>
C s
par t,</w>
kg )</w>
congen ital</w>
W T</w>
C d</w>
AP -1</w>
0 /
mi a,</w>
il i
hund red</w>
ha z
b eli
aggres sive</w>
ME NT
weigh t,</w>
parkinson ian</w>
n one</w>
mon onuclear</w>
lat ency</w>
gen iste
cyt e</w>
accoun t</w>
S yn
7 %)</w>
6 6
ml /
id ation</w>
amino transferase</w>
S S
N ot
D ata</w>
towar ds</w>
s on</w>
en ed</w>
dobut amine</w>
deoxy chol
de m
comple ted</w>
children .</w>
carcin ogenesis.</w>
bi polar</w>
anxi ety</w>
therap ies</w>
signall ing</w>
pre feren
lact ate</w>
ison iaz
inf used</w>
electroph ore
der m
alle vi
St udi
sig n</w>
pul se</w>
produc tion,</w>
di ox
cor d
attenu ate</w>
S uc
Over all,</w>
F rom</w>
syndrome ,</w>
suspec ted</w>
subst ance</w>
menopa usal</w>
hyperpla sia</w>
et opo
as es.</w>
acqu ired</w>
MC F
normal ized</w>
N QO
vasodi lat
stro k
predic tive</w>
ol e-
muscar inic</w>
lip id
enhanc ing</w>
effici ent</w>
earli er</w>
dors al</w>
a ud
CA 1</w>
(O R</w>
olog ous</w>
i dis
elec tive</w>
cholest atic</w>
al oxif
Sev ere</w>
PG E2</w>
B D
Activ ation</w>
20 -
arc h</w>
4 %)</w>
suc cin
sit u</w>
prop ion
om al</w>
hal f-
F as
D ox
Cac o-2</w>
- based</w>
(3 0</w>
s ha
respec tive</w>
prol actin</w>
femal es</w>
constitu tive</w>
ati tis</w>
adol esc
50 ,</w>
toler ability</w>
gentam icin</w>
carcin oma.</w>
U S
L- NA
Alzheim er's</w>
9 5</w>
sol ution</w>
pol ar
nalox one</w>
a ir</w>
] -
ul c
complex es</w>
V K
v al</w>
respons es.</w>
on dro
factor s,</w>
cr yst
clop id
ble eding</w>
Simil ar</w>
P 2
sec ret
os tic</w>
n mol/
S L
p ic
hal f</w>
ce phal
ce f
R el
CD 4
est er</w>
cyt oplasmic</w>
cor tex
coag ulation</w>
antipsych o
H F
(N S
one ph
metast asis</w>
it ory</w>
an ol</w>
po d
mo tion</w>
T .</w>
17 beta-
valpro ate</w>
stimul ates</w>
opl atin</w>
ocy te
j a
M K
H ear
threat ening</w>
se mi
ocl opr
in haled</w>
fi x
exc ess</w>
am ide.</w>
ab le.</w>
EC G</w>
( 5-
iso forms</w>
em erg
beta 1</w>
TI ON:</w>
Immun o
F if
3 A</w>
-2 ,
s ou
s ].</w>
ocardi al</w>
nause a</w>
incl u
g p</w>
anti gen
R et
Ca2 +</w>
Ap opto
5 ),</w>
1A 1</w>
10 %</w>
(1 -
intr insic</w>
dog s.</w>
adi pose</w>
G R
control le
chym al</w>
cap able</w>
U -
Qu er
Ar g
pregn ant</w>
op tic</w>
influ enced</w>
fibrobl ast</w>
dec line</w>
co bal
b cl
transplant ation.</w>
metabolis m,</w>
k ind
depress ed</w>
consist ed</w>
case- control</w>
apopto sis-
-1 ),</w>
sm all
pro- inflammatory</w>
id en
death ,</w>
requir ing</w>
pitu itary</w>
iz ation,</w>
hypo kal
) ).</w>
t on
s plic
re d,</w>
occ u
microscop y</w>
l yc
aug mented</w>
alph a.</w>
0. 4
transform ing</w>
is m.</w>
infiltr ation</w>
il .</w>
compound s.</w>
W il
M it
AC T</w>
p 21</w>
neut rop
metabol izing</w>
liqu id</w>
conver sion</w>
al y
Ph en
5 1</w>
( EC
vincrist ine</w>
ver s
ret ard
penicill amine</w>
par allel</w>
memb ers</w>
loc us</w>
l up
is su
is he
hom ocyste
N- terminal</w>
E uro
Cy t
CAM -1</w>
ribavir in</w>
ogene sis,</w>
numb ers</w>
it s.</w>
hour s.</w>
publ ished</w>
invol ve</w>
del ta</w>
P- rib
F A</w>
BP )</w>
symptom s,</w>
lif e-
entr al</w>
volunte ers</w>
tic ,</w>
tac rolimus</w>
requi res</w>
py rene</w>
f all</w>
convul sive</w>
SY5 Y</w>
3 '-
tetrac hlorodibenzo-p-
ni acin</w>
mix ture</w>
Studi es</w>
DNA -
CYP1A 2</w>
B ax
2 ;</w>
surviv al.</w>
region al</w>
G ene</w>
A Q
9 8
yl ated</w>
vie w</w>
tiv ari
substanti al</w>
ne oplastic</w>
ful l</w>
exc re
ent er</w>
anti bio
( s)</w>
trem or</w>
str ain
prec ip
prac tic
occu pati
manner ,</w>
increas ed.</w>
doxorubic in-induced</w>
O P
EL IS
) ),</w>
(e .g
(- )-
respon ded</w>
pto m</w>
neurolep tic</w>
mod e</w>
establ ish</w>
UV EC
S K
C57B L/
( r</w>
un changed</w>
str ains</w>
initi ally</w>
growth .</w>
amoun ts</w>
Signific ant</w>
P XR</w>
ti d</w>
in dependently</w>
AT O</w>
+ )</w>
(M D
mes sen
k el
cross over</w>
angi ogenesis</w>
specific ity</w>
pro min
ol der</w>
mT OR</w>
em bol
cycl es</w>
Si x</w>
N either</w>
7 .</w>
strepto zotoc
p on
otoxic ity,</w>
ol ec
ograph y.</w>
epid ural</w>
days )</w>
ch ing</w>
autis m</w>
aldo sterone</w>
II ,</w>
we ak</w>
ut ure</w>
co ding</w>
anim als,</w>
D op
st en
spectro metr
res on
par allel
n et
brom ocript
bil irub
beg inning</w>
Chang es</w>
us e,</w>
prophyl axis</w>
ev er</w>
di arr
barri er</w>
transform ed</w>
sol id</w>
organ o
fav or
add res
CYP 1B1</w>
sequenc ing</w>
em at
con nec
calcul ated</w>
N I
Cardi ac</w>
prednisol one</w>
p H</w>
hemorrh agic</w>
deli very</w>
bor n</w>
M icro
H (2)O
year s)</w>
st om
plac ental</w>
par tly</w>
consc ious</w>
biop si
atten tion</w>
th o
optim al</w>
i .</w>
enc y,</w>
METHOD S</w>
Hi gh</w>
3 0%</w>
ur g
un known</w>
magnit ude</w>
gen otoxic</w>
f iltr
block s</w>
assa ys.</w>
amin o-
S B
RNA s</w>
t ended</w>
rap amycin</w>
kin in</w>
ing estion</w>
he av
di hydroxy
cal cit
E lec
6 00</w>
tuber cul
sul ind
reach ed</w>
op ril</w>
olan zapine</w>
intrac ere
describe d.</w>
6 7</w>
6 %)</w>
ter at
resol ution</w>
qu ality</w>
ps ori
progn ostic</w>
microsom al</w>
loc i</w>
id ate</w>
bacter ial</w>
adul ts</w>
PT E
(G SH
pur ified</w>
op recip
ide -
addi tive</w>
T A
GS T</w>
Con tro
so ,</w>
neph ritis</w>
infarc tion.</w>
hel p</w>
g ab
enzym es,</w>
en s</w>
at e-induced</w>
statis tical</w>
normot ensive</w>
meas uring</w>
Scal e</w>
CI :</w>
tr act
scop ol
rele v
po i
ol ar
hybri diz
cysti tis</w>
concentr ations,</w>
ch ondro
bel ow</w>
t ent</w>
om al
min )</w>
immun ob
ci pro
Si x
O S</w>
success ful</w>
meth ion
inf er
W ith
K 1</w>
v ar
particip ants</w>
g )</w>
M MA
LNCa P</w>
C T</w>
re l</w>
medi a</w>
fas hi
em ph
STR ACT</w>
O P</w>
N i
1 2,</w>
underst and</w>
toxic ities</w>
thromb o
s ar
modul ated</w>
intrac ranial</w>
inflamm ation,</w>
cortis ol</w>
bac k
as cor
as best
Ex perim
As2O 3</w>
1 4.
) ]</w>
requir e</w>
i. p.</w>
brady cardi
ar tic
anti- apoptotic</w>
7 8
5 4</w>
t end
st ly</w>
exc essive</w>
ess el
de tox
chrom atin</w>
carb oplatin</w>
UN CAT
TR UNCAT
E 2
(AB STRACT</w>
( r
st rom
resid ues</w>
pro ved</w>
pestic ides</w>
medul l
m ine</w>
literat ure.</w>
W OR
s acr
p2 1
microgram s</w>
amino phen
adv ant
v essel
opoi etic</w>
k age</w>
cy st
bec ome</w>
adri amycin</w>
ac y</w>
H D</w>
scaven g
rang ing</w>
mo graph
am ate</w>
H 2O
Compar ison</w>
vari able</w>
ur ia,</w>
transi tion</w>
o il</w>
methyl transferase</w>
manifest ations</w>
i br
cy s
carr ying</w>
z ym
respon d</w>
reson ance</w>
de sign
WOR DS)</w>
TRUNCAT ED</w>
M C</w>
summar y,</w>
mang anese</w>
lat er,</w>
dram atically</w>
respectively )</w>
on ectin</w>
ne oplas
methad one</w>
T ri
A z
n atal</w>
h lor
condi tions,</w>
angi ogenic</w>
af en
9 .</w>
v ical</w>
ther n</w>
neuropath y.</w>
meto prolol</w>
ig n</w>
ic ardi
hepat ocarcin
5 8
sed ation</w>
se ,</w>
reticul um</w>
os ensi
magnesi um</w>
anti epileptic</w>
C yp
C 3
A fr
5- az
proc ess.</w>
ot ec
measure ment</w>
measure d.</w>
compar ing</w>
at es,</w>
antidepress ant</w>
N H
6 ).</w>
poly phen
orub icin</w>
no v
neuro degenerative</w>
gen e-
cyclooxygenase- 2</w>
PPA R-
Hi gh
- negative</w>
- independent</w>
tra um
omy cin
neutroph il</w>
ing ly</w>
fibro sis.</w>
condition ed</w>
Simil arly,</w>
Ca (2+
y -induced</w>
upreg ul
under g
str ain</w>
se em</w>
scop olamine</w>
or din
inter ference</w>
haloperid ol-induced</w>
b us
anti proliferative</w>
Mn SOD</w>
vom iting</w>
mg/kg/ day</w>
methyl ated</w>
kine tic</w>
con sequences</w>
S ome</w>
5 9</w>
(A L
relap se</w>
pren atal</w>
plac ed</w>
inter mediate</w>
Thir ty-
(G ST
( a
ste p</w>
separ ate</w>
ris k.</w>
reac tion.</w>
method s</w>
kidne ys</w>
correl ate</w>
abdom y
T LR
PK C</w>
4 50</w>
par acetam
in- treated</w>
e f
diure tic</w>
deli ri
combin ations</w>
ap lastic</w>
S m
HI V</w>
z inc
tr uct
ne u
frag mentation</w>
carcin ogen</w>
insuffici ency</w>
follow- up
complic ated</w>
SE T
AIM S:</w>
we ster
vas opres
tubul e</w>
a wa
SH- SY5Y</w>
P ost
ul fir
ris ks</w>
p seud
f el
cholest asis</w>
chloro thiaz
at er
anal og</w>
L 1</w>
Further ,</w>
C P</w>
proteas ome</w>
pro t
modi fy</w>
ke l</w>
equival ent</w>
ampl it
4 00
(- )</w>
tumor s,</w>
tran s</w>
lu te
gu ine
g on
frequ encies</w>
differenti ation.</w>
N- methyl-
MATERI ALS</w>
re si
non steroidal</w>
hydro chloride</w>
cl ose</w>
anesthe tic</w>
F lu
2 '-
ve -
uc in
stit uted</w>
seg ment</w>
pol lut
phenobarb ital</w>
overexpress ing</w>
mes oth
l um
ar ide</w>
He L
D ).</w>
5 /
wor kers</w>
sen esc
s light</w>
quin ol
protoc ol</w>
oc ca
amin onucle
ac etic</w>
S ).</w>
E C</w>
C ell
valpro ic</w>
under taken</w>
over -
os arcoma</w>
eti ology</w>
bind s</w>
ar -
T R</w>
M ed
Li ver</w>
D B
4 9</w>
ell it
descri b
O H
tion ally</w>
seiz ures,</w>
messen ger</w>
bis phenol</w>
attenu ation</w>
U r
HL A-
0.00 1),</w>
, 000</w>
ret te</w>
period s</w>
ocy an
mRNA ,</w>
heav y</w>
az athi
W n
yl ation</w>
un dic
l an
in dex
i odi
evid enced</w>
event s.</w>
O V
EE G</w>
group s:</w>
deoxychol ic</w>
N ic
Mul ti
I d
Gen etic</w>
wester n</w>
thromb otic</w>
placeb o,</w>
ozyg ot
ous ly,</w>
ob ese</w>
nitroglycer in</w>
la y
ine d,</w>
he modi
ation )</w>
D ex
7 3</w>
2,3,7,8- tetrachlorodibenzo-p-
0. 4</w>
patient ,</w>
explo red</w>
RA R
wa ys</w>
t aining</w>
reten tion</w>
pro maz
p uro
n im
ment s.</w>
mal on
ing u
gl and</w>
con current</w>
bac k</w>
and s</w>
H a
2 A
0 )</w>
point es</w>
ir rit
epitheli um</w>
PA -induced</w>
thromb in</w>
side- effects</w>
neuro toxic</w>
mes en
medi ators</w>
leuk otri
idi opathic</w>
emergen cy</w>
cur ve</w>
catech ol
b ine</w>
NS CL
CN S</w>
4 6</w>
uter ine</w>
tren d</w>
suppress ing</w>
pr inc
perfor med.</w>
clo zap
b est</w>
5- HT</w>
(T CD
up stream</w>
time -
n umerous</w>
mRNA .</w>
lo ad</w>
fe wer</w>
immun oprecip
haplotyp e</w>
diltiaz em</w>
defec t</w>
VK OR
6 3</w>
ymptom atic</w>
psych otic</w>
enzym es.</w>
canc er
blot ting</w>
as p
arsen it
H M
C ),</w>
8 %)</w>
r al</w>
avail ability</w>
P N
7 8</w>
there fore,</w>
te d
substanti ally</w>
sub set</w>
as es,</w>
C l</w>
transcrip t</w>
simil ar
progn osis</w>
pre ad</w>
p <
le g
dose- response</w>
control ling</w>
ap o
amlo dipine</w>
0.0 1),</w>
poss ess
ion s</w>
fol lic
filtr ation</w>
LP S-induced</w>
1 3-
0 %)</w>
strateg ies</w>
sal ic
ob vi
m ellit
lid oca
k D
gen ome-wide</w>
STAT 3</w>
I L</w>
sym ptom</w>
m ing</w>
kg (-1
growth ,</w>
gen it
col onic</w>
anc er</w>
amin og
T- cell</w>
sur ve
pres um
hy pe
di men
atro pine</w>
analys ed</w>
amphet amine-induced</w>
NADP H</w>
M O
Hear t</w>
AIM :</w>
( rs
time .</w>
te z
nit r
label ing</w>
kg -1</w>
hypo thalam
heter ogene
hepat ocytes.</w>
famil ies</w>
end oplasmic</w>
const ant</w>
character ization</w>
MT T</w>
o [
junc tion</w>
intr am
ap ol
a ox
P -induced</w>
1 5.
-2 .</w>
v acu
sud den</w>
posi tively</w>
plas tic</w>
physi ologic</w>
om a,</w>
id ov
histopath ological</w>
hemo globin</w>
can not</w>
METHOD :</w>
E lev
CYP2 B
BACKGROUN D</w>
val ent</w>
sub -
s kin
popul ations</w>
kin ase-
L ),</w>
syndro m
os pas
modi fic
met oclopr
mRNA s</w>
kine tics</w>
ith ro
iden tical</w>
gene sis.</w>
e NOS</w>
c ic
S T</w>
An im
4, 5-
st ep
ser ine</w>
sacr ific
leuk emic</w>
emplo yed</w>
al in</w>
acid -induced</w>
C hi
34 4</w>
ur ia.</w>
trans amin
precip it
i.v .)</w>
hyper glyc
dos es,</w>
alkal ine</w>
MD R1</w>
6 9
tiv ely,</w>
ro tid</w>
retin oid</w>
r aloxif
pan ic</w>
o edema</w>
interven tion</w>
ifosfam ide</w>
( range</w>
mac ro
induc tion.</w>
fl uc
extrac ts</w>
cytometr y</w>
cer vical</w>
alter s</w>
SU RE
G R</w>
Ad verse</w>
res .</w>
psych osis</w>
ol /
of -
midazol am</w>
hormon al</w>
great ly</w>
10 00</w>
wil d</w>
ser ve</w>
lymph ocyte</w>
it sel
e ).</w>
cod on</w>
avoid ance</w>
ast ing</w>
H N
3 0-
re mia</w>
hydroxyl ation</w>
haloth ane</w>
gene tically</w>
b .</w>
ass es
antioxid ants</w>
S yst
L Y
He pati
A -induced</w>
rever si
p. o
low est</w>
hypoten sion.</w>
as h
S N
ME A
I ts</w>
4 0%</w>
y o
x anth
th em
sid es</w>
phosphoryl ation.</w>
contribut ing</w>
chron ically</w>
V al
C al
in /
gh ts</w>
de tail
cardiomy opathy.</w>
MEA SURE
AH R</w>
ure -
t ot
t ors</w>
re modeling</w>
lesion s.</w>
ath yro
S pec
M K-
test ,</w>
stres s
sensi tized</w>
ric h
erythro poi
demonstr ating</w>
ci ga
chloro quine</w>
ca re
we l</w>
shor ten
line ar</w>
epilep sy.</w>
e ),</w>
M N
D P</w>
CB 1</w>
C ap
w ise</w>
tez omi
rex pression</w>
re placement</w>
pre lim
micro M,</w>
j oin
is ms</w>
in sec
exer ted</w>
con c
com mun
antagon ism</w>
S F
M I</w>
Hy dro
Dru g</w>
(2) )</w>
ques tion
per itone
k appa</w>
ja undic
inhibitor .</w>
biomar ker</w>
allo dyn
ad es</w>
O ve
( +/-
insi ght</w>
factor- alpha</w>
col itis</w>
anti coagul
Quer cetin</w>
M echan
6 ),</w>
ur k
specimen s</w>
mo bility</w>
leuk emia.</w>
k es</w>
he re
T oxic
IC 50</w>
thresh ol
rod ent</w>
rele ased</w>
re ference</w>
normal .</w>
foun d.</w>
di azep
clopid og
be aring</w>
arter ies</w>
SET TI
R ole</w>
st in
small er</w>
se l</w>
n ai
mat ur
label ed</w>
im ipr
at ax
angiotensin- converting</w>
DO X</w>
C ocaine</w>
B E
suppor ted</w>
sou ght</w>
phy to
ox amine</w>
li st
influ ences</w>
aro mat
ap ine</w>
am bul
abrog ated</w>
T oge
tivari ate</w>
ti tr
recruit ment</w>
on it
f inal</w>
ethyl ene</w>
controlle d,</w>
compound s,</w>
acro le
T E
thi one
subst ances</w>
overexpress ed</w>
os tig
oc occ
lim it
graf t</w>
gemcit abine</w>
T um
u st
striat um</w>
nan op
min ant</w>
lip ide
fluoresc ent</w>
di aph
tro glitazone</w>
star t</w>
ro w
rele as
re activity</w>
oxygenase- 1</w>
interfer on-
S D
8 8
ti d
ter s</w>
promin ent</w>
post natal</w>
aten olol</w>
analog ue</w>
B B
simil arly</w>
review ed</w>
progres sion.</w>
nicot inic</w>
ne ur
inter mit
hydro chlorothiaz
hepar in</w>
de si
compar ative</w>
cad mi
cad her
b ase</w>
acet aminophen
T F
P-rib os
N one</w>
DC A</w>
substitu tion</w>
per f
om ers</w>
le t</w>
T A</w>
Col lec
6 1</w>
o k</w>
mal form
magne tic</w>
ic illin
effici ency</w>
coca ine.</w>
cis -
cataly zed</w>
vol t
variabl es</w>
olec ular</w>
nitroprus side</w>
n es
fl ut
famil ial</w>
en ous</w>
as cular</w>
NA C</w>
(T NF-
suff ering</w>
pestic ide</w>
obarb it
hall ucin
cont act</w>
chi ld</w>
AL DH
synthe sized</w>
su ffered</w>
predn is
pol yp
disturb ances</w>
bo wel</w>
adren al
Euro pe
ET -1</w>
us h
levodop a</w>
lep tin</w>
infu sions</w>
i otic</w>
cy clin
beta- adrenergic</w>
ac he
CYP2D 6</w>
vol u
tr adi
thrombocytopen ia</w>
tetr azol
synthe sis.</w>
sequ ently,</w>
replic ation</w>
physi ci
mon ocyte</w>
metabol ized</w>
lin k</w>
f ish</w>
en e,</w>
H sp
van com
puro mycin</w>
elem ents</w>
c ot
adduc t</w>
T /
He al
9 6</w>
s low
mid d
in ser
g ,</w>
con sequence</w>
A t
tre x
trans membrane</w>
om at
form ul
dela y</w>
ch ec
amelior ated</w>
X ,</w>
SH R</w>
R 2</w>
ATI ON
( from</w>
regul ation.</w>
mg/kg ).</w>
life- threatening</w>
l is
investig ations</w>
g el
ex trem
eth yl</w>
es /
ec oxib</w>
diff use</w>
SC s</w>
Ove rexpression</w>
O 2</w>
M ice</w>
C K
2 5%</w>
wor k
vascul itis</w>
transf er</w>
ol e
m um
fibr ate</w>
expos ures</w>
be zaf
as pec
ar one</w>
al op
S D</w>
IL-1 beta</w>
I /
CYP2A 6</w>
Al so,</w>
ycl ine</w>
r ag
oph er
opath y,</w>
mus cle
mol ar</w>
favor able</w>
bir th</w>
ar y
T en</w>
reli ef</w>
pum p</w>
prelim inary</w>
p icro
n a</w>
mo vements</w>
inten sive</w>
identifi ed.</w>
blood -
an tr
R OD
(S OD
( ERK
pro pose</w>
on omic</w>
iso form</w>
il ateral</w>
dep ri
de sign</w>
d al
ca rotid</w>
S MC
S /
PK C
Cr (V
CYP2C 9
1 4-
1 *
( 4.
pyr idine</w>
phenyl )
dipyridam ole</w>
carb oxy
PATIENT S</w>
HIF-1 alpha</w>
2. 0</w>
res or
p5 3,</w>
or rh
alcoh olic</w>
H U
CA SE</w>
C ancer</w>
Apopto sis</w>
AK T</w>
techniqu e</w>
clar ify</w>
amph oter
Long -term</w>
HeL a</w>
tiv ir
relev ance</w>
ot ox
n utri
en anti
concentr ation.</w>
ar in</w>
Intr av
v en</w>
selen ium</w>
s pl
prote ase</w>
propran ol
f uture</w>
episod e</w>
ep sil
cyclo hex
H u
wom en.</w>
vis c
un related</w>
umb il
r am
my opathy</w>
less er</w>
intr a-
i b</w>
def ect
G .</w>
Del ta
Bcl- x
2 C
tum or-
ther mal</w>
resul ts,</w>
on c
in her
immunohist ochemical</w>
e rec
de -
atheroscler osis</w>
arach id
MDA- MB
E V
7 6</w>
sion s,</w>
p ly</w>
oxidi zed</w>
on azole</w>
lipopolysacch aride</w>
bron ch
benef its</w>
PI3 K</w>
vom it
tu be</w>
sol u
s por
nucle oti
head ache
R is
I ),</w>
G 2/
Con ver
3 T
un affected</w>
umbil ical</w>
struct ures</w>
pre pared</w>
om as.</w>
occlu sion</w>
infec tion.</w>
genotyp ed</w>
electr ical</w>
detox ification</w>
cys tic</w>
5 6</w>
volu me
transcrip ts</w>
rele ase.</w>
pro found</w>
ket ocon
intraperitone ally</w>
dose- related</w>
a :</w>
S up
M ethyl
F R</w>
E valu
C arb
6 00
. (ABSTRACT</w>
read y</w>
olog ic
form ation,</w>
foc i</w>
creat ine</w>
chemo kine</w>
activ it
acetylchol inesterase</w>
R ).</w>
P ),</w>
Mut ations</w>
CC l
C ys
-1 00</w>
su matri
sumatri pt
re m
precur sor</w>
om ethyl
occupati onal</w>
he m
fr uct
experim ent</w>
b al</w>
ain .</w>
AT P-
(2 00</w>
o ural</w>
nat ri
intoxic ation</w>
ill in</w>
M R</w>
Collec tively,</w>
CX CR
/ -</w>
rang ed</w>
pathophysi ology</w>
p el
malon di
lim b</w>
dri ven</w>
cyclo oxygenase</w>
am ide-induced</w>
6 4</w>
(AD P-ribos
un chang
k ast</w>
i ,</w>
hemat opoietic</w>
g ir
ex cl
diabet es.</w>
assa yed</w>
T P</w>
F as</w>
As(2)O (3)</w>
5 8</w>
strom al</w>
restric ted</w>
im mediate</w>
determin ation</w>
a emic</w>
S V
vel oc
trans mit
ta x
re perfusion</w>
peritone al</w>
nov o</w>
neuropath ic</w>
natri ure
lac king</w>
en se</w>
am il
acetyl ation</w>
I AP
DI SC
CA R</w>
7. 5</w>
5 7</w>
- free</w>
ta il</w>
r ich</w>
phenomen on</w>
mo bil
min /
immunosup pressive</w>
ectom y</w>
di verse</w>
depend ent.</w>
aberr ant</w>
R S</w>
L ).</w>
2,3,7,8-tetrachlorodibenzo-p- dioxin</w>
pharmac ologic</w>
ph ase.</w>
nic kel</w>
g p
f in
coun t</w>
U nit
SETTI NG
0. 3
+/ -1
z idov
sy ,</w>
subjec tive</w>
os cop
nor adrenaline</w>
mut ants</w>
infec tions</w>
f it
cannabin oid</w>
PA ,</w>
B H
9 %)</w>
rou gh</w>
ou re
om ep
neu tr
mo ther
lup us</w>
en rich
amphoter icin</w>
aggreg ation</w>
(2 ),</w>
( N</w>
simult aneous</w>
plac e</w>
p up
on at
morb idity</w>
environ ment</w>
docetax el</w>
direc ted</w>
d ual</w>
Sub jec
7 7</w>
subjec ts,</w>
press or</w>
medi ator</w>
f ind</w>
exhib its</w>
elimin ation</w>
contrac ep
consist ing</w>
ar y,</w>
Or al</w>
tak e.</w>
su it
s l
pharmac od
inter act</w>
cho ice</w>
asth ma.</w>
TRA IL</w>
JN K
I D
17 -
1 -1</w>
ript yl
rh abdomy
reg ular</w>
recipi ents</w>
oche mic
cyt otoxicity.</w>
cerebell ar</w>
biosynthe sis</w>
an ion</w>
am ide
agg ra
Ph ase</w>
Elec tro
E GF</w>
2 D
res em
orph ine</w>
hepati tis.</w>
e x</w>
cyt oplas
correl ates</w>
child hood</w>
aut osomal</w>
R s</w>
P hy
As sociation</w>
war d</w>
th el
t ing
quanti fied</w>
pro genit
ne ar</w>
mo vement</w>
ibr ate</w>
dis appeared</w>
cour ses</w>
ci me
T e
SETTING :</w>
ER -
ur in
hyp oxic</w>
P- glycoprotein</w>
C lin
7 ).</w>
x -
trans activation</w>
toc opher
to ol</w>
stit ute</w>
st ably</w>
sil ic
respon ders</w>
reg ard</w>
fo s</w>
es ul
dep olar
cont ained</w>
arti cles</w>
(C D
(0. 5</w>
suppor ts</w>
sist ent</w>
sign als</w>
o x</w>
nat ure</w>
hear ts</w>
form in</w>
fibr in
ation ;</w>
al ready</w>
ac idi
ac e
simult aneously</w>
schizophren ia.</w>
poison ing</w>
ogen etic</w>
meth od.</w>
mesen chymal</w>
liver s</w>
he mod
defic it</w>
cyclospor ine</w>
ab stin
a dequate</w>
ROD UC
M ore</w>
L eu
INT RODUC
B AL
2 5,</w>
( 4</w>
sem ide</w>
dist ingu
cirrho sis</w>
S r
AS A</w>
/ d
(A h
vers ely</w>
schizophren ic</w>
repe at</w>
pla qu
on ium</w>
hist or
gentam ic
dig oxin</w>
bor tezomi
biopsi es</w>
app ing</w>
am it
ain ,</w>
C R</w>
A V
1 5,</w>
ves sel</w>
tre mor
transcrip tion-
sulind ac</w>
sub cut
stimul i</w>
pro motion</w>
paren tal</w>
n ociceptive</w>
m )</w>
injec tion,</w>
di phenyl
c ,</w>
asses sed.</w>
K56 2</w>
Ac et
(i. e.,</w>
str and</w>
main tain</w>
i po
e- specific</w>
d one</w>
classi cal</w>
chang es,</w>
amne sia</w>
(D E
wa ve</w>
to ph
sel y,</w>
ben ign</w>
S LC
Cur cum
8 5</w>
25 (OH)
triglycer ide</w>
spec ies.</w>
resid ual</w>
kin ase,</w>
k B</w>
O c
Immuno hist
7 5
ra rely</w>
hormon e-
ful minant</w>
en -
ar yn
T G
GL UT
spec i
ot om
neutrophil s</w>
mis sense</w>
ion ic</w>
ex ter
def ine</w>
co ordin
aromat ase</w>
QT c</w>
-1 /
(M MP
subjec t</w>
repa ir
promot er.</w>
on id
macroph ages.</w>
interval ,</w>
inte rest</w>
ep idemi
ation :</w>
anesthe sia.</w>
ab le,</w>
8 ).</w>
(N O)</w>
(I L-
withdraw al.</w>
w k</w>
stres s-
signific ant
phenyleph rine</w>
mg .
i -
grad ually</w>
depres sion.</w>
M M</w>
F unc
( >
restric tion</w>
recogn ition</w>
prophyl actic</w>
lo id
in s,</w>
compar ison
clon id
al um
ag e
Im port
INT ER
z ing</w>
ot oxin</w>
ocyto sis</w>
iso flurane</w>
immunore activity</w>
entr y</w>
com e</w>
cle a
chlor promaz
ambul atory</w>
Unit ed</w>
IC (50)</w>
(P PAR
un usual</w>
synthe sis,</w>
la sia</w>
f ill
describ es</w>
N ,</w>
INTRODUC TION:</w>
8 ),</w>
xenob io
we ver</w>
stere otyp
sol ute</w>
soci al</w>
secre tion.</w>
over dose</w>
nitro gen</w>
fib ers</w>
as ymptomatic</w>
anti sense</w>
acceler ated</w>
U 9
T NF</w>
MA IN</w>
DISC US
B CN
0. 6</w>
s ome
recor d
otec an</w>
os e-
neuro toxicity.</w>
ir reversible</w>
entric ular</w>
U )</w>
18 .
vari ations</w>
treatment s.</w>
trans duc
sp i
sle ep
se arch</w>
po ster
p 65</w>
n ude</w>
n ational</w>
ill ustr
fen flur
ent ate</w>
arthri tis.</w>
ST UD
N T</w>
0.0 1</w>
- L-
un i
synerg is
rhyth m</w>
provid ing</w>
non- small</w>
increas ed,</w>
flox ac
consist ently</w>
activ ators</w>
achi eve</w>
V it
R a
AD R</w>
6 6</w>
50 -
12 5</w>
uc asi
intermit tent</w>
ibu profen</w>
comp ris
analy ze</w>
S ec
S W
thi op
resist ance,</w>
poss ess</w>
morph ology</w>
m s,</w>
hypoxi a-
UN E
T O
PON 1</w>
PI3 K/
E ach</w>
C p
t onic</w>
supple mented</w>
myocl on
m os
factor ,</w>
ev ol
di alysis</w>
ciga rette</w>
9 ).</w>
20 ,</w>
tro p
s atis
obes ity</w>
ly co
lim it</w>
inhal ation</w>
compar t
N E
3 ;</w>
(P C
stimul ation.</w>
prost atic</w>
proble m</w>
persist ed</w>
per fu
echocardi ography</w>
dis ulfir
diarr he
d end
ac ted</w>
B et
6 *
3- methyl
prov en</w>
profil ing</w>
post menopausal</w>
nephropath y.</w>
min ated</w>
ishe d.</w>
insi ghts</w>
guine a</w>
ep irub
dos e-</w>
ang ial</w>
APA P</w>
) ].</w>
( 5.
x ,</w>
pos ite</w>
ne a</w>
mim ic
l ind
ir t
hyper prolact
appro ved</w>
S even</w>
H CC
CA )</w>
r e</w>
le ar</w>
inter f
interf ere</w>
car nit
be at
acc ept
a sis,</w>
N on
Ei ght</w>
7 4</w>
(2 5</w>
truct ural</w>
par athyro
offsp ring</w>
microscop ic</w>
hormon es</w>
S R</w>
MDA-MB -2
relax ation</w>
port al</w>
olig onucle
og lob
dis play</w>
an omal
P- 2</w>
6 2</w>
3- kinase</w>
xenob iotic</w>
som n
rati o,</w>
propo fol
po w
pe op
mg .</w>
ext ended</w>
deacetyl ase</w>
da un
beta- catenin</w>
appa ren
TCD D
Pro tec
P H
tr im
lung s</w>
hypoten sion,</w>
hemat ologic</w>
form ing</w>
death s</w>
coll ec
ap ical</w>
Y :</w>
Evalu ation</w>
C RE
(P B
pas sive</w>
p g/m
o is
not .</w>
na ph
n g/
mon ocytes</w>
mo od</w>
hyper ther
foc used</w>
dys function,</w>
complic ations.</w>
cobal t</w>
attac ks</w>
ag ain</w>
PA N</w>
DISCUS SION
Ca ucasi
1. 2</w>
w is
pro- apoptotic</w>
miR -2
ine :</w>
glomerul oneph
constitu tively</w>
classi fied</w>
M 2</w>
Id enti
A E
y ).</w>
wh at</w>
reproduc tive</w>
ca the
b er
L V
B 2</w>
(T NF
tri pt
tol u
sm all-
raz ol
morph ine-induced</w>
lin kage</w>
intram us
equ ally</w>
differenti ation,</w>
behavi oural</w>
anti apoptotic</w>
Europe an</w>
Co A</w>
4 4
ucle ar</w>
sequ ential</w>
pathwa ys,</w>
ol act
necro sis.</w>
mat ter</w>
ma ze</w>
lamiv ud
immunohist ochemistry</w>
azol e,</w>
attribut able</w>
ane ur
am yg
St at
P- gp</w>
10 )</w>
- dose</w>
(H D
stat us.</w>
process ing</w>
as e)</w>
a fferen
Ne w</w>
B I
s ot
ra ised</w>
ex pec
determin ing</w>
ba sic</w>
aneur ys
amyg dal
DISCUSSION :</w>
ren in-
receptor- mediated</w>
phosphoryl ation,</w>
og lyc
mic ron
kg ,</w>
fentan il</w>
es artan</w>
dem enti
Ox id
tradi tional</w>
si RNA
princ ip
mg/kg .</w>
go al</w>
ep inephr
don or</w>
diclofen ac</w>
creat in
bra in,</w>
an e,</w>
FK 50
An g</w>
1 1-
st atin</w>
ra y</w>
protein -1</w>
ol ide</w>
no vi
metallo thione
mes angial</w>
lab el</w>
j ac
hydro carbon
hybridiz ation</w>
enzyme -
benzodi azepine</w>
atroph y</w>
alter ing</w>
M any</w>
thyro idis
res ,</w>
releas ing</w>
oblas t</w>
ket o
iti s,</w>
fol d,</w>
fi ber</w>
es cal
depend ence.</w>
c all
b .
T GF
S u
Intrav enous</w>
Dru g
B u
AT RA
8 7</w>
(ER )</w>
par as
op rine</w>
n ess,</w>
il ic</w>
estic ular</w>
d entate</w>
amit riptyl
aminonucle oside</w>
PPAR alpha</w>
N-acetyl cysteine</w>
ure th
rat e-
pi lot</w>
o ventricular</w>
no de</w>
methion ine</w>
ish man
incid ences</w>
flu or
embry os</w>
c- fos</w>
anaesthe sia</w>
aden omas</w>
P DE
G2/ M</w>
AM P-
6 8</w>
ulf an</w>
sup ra
s pati
comp ens
amy loid</w>
Suc h</w>
(P =0.0
to ok</w>
to bac
shor ter</w>
par aox
in s.</w>
immunob lot
es ).</w>
cl ass
Th er
PA RP
MC P-1</w>
HI V
D U
C ).</w>
B CL
10 (-1
vas ospas
tivir al</w>
th elial</w>
st ,</w>
phosph o-
n =
lymph oblastic</w>
isoproteren ol-induced</w>
fac t</w>
emph asi
decreas ed.</w>
dat a,</w>
ca ud
adip ocytes</w>
Heal th</w>
HE K
Gl ut
E arly</w>
AC )</w>
visc eral</w>
thi o
plac ent
pa rent</w>
m -
ische mia.</w>
insec tic
Z -
Z )</w>
G r
B l
(1 5</w>
x .</w>
th or
relationshi ps</w>
kD a</w>
en sion</w>
carbam azep
Amer ican</w>
1 6.
re th
mas sive</w>
leukotri ene</w>
le thal
ind ina
dyskinesi as</w>
concentr ation,</w>
cisplat in-induced</w>
chemo therap
c ent</w>
br af
all- trans</w>
(e.g .,</w>
var ying</w>
transl ational</w>
ous ly.</w>
lat er.</w>
hyper calc
gon ad
disorder s,</w>
activ ities,</w>
S G
CC )</w>
AQ P
vul ner
ver sity</w>
re pression</w>
odi pine</w>
nife dip
iz ed.</w>
deoxy cy
con served</w>
Z D
F l
Conver sely,</w>
6 /
(ADP-ribos e)</w>
ulc er</w>
su sp
oph thal
ocycl ine</w>
geniste in</w>
e- associated</w>
chlor am
P B</w>
F OX
Differen tial</w>
- sensitive</w>
(A P
stimul atory</w>
ril ,</w>
resveratro l,</w>
knowledg e,</w>
im pl
human s,</w>
el ve</w>
Toge ther,</w>
9 80
veloc ity</w>
suit able</w>
pro fi
pa w</w>
ot roph
ol in</w>
od g
norm ally</w>
mucos a</w>
ha ir</w>
back gro
analog s</w>
D M
C u</w>
B is
( max
sh ock
seve rely</w>
path ology</w>
main taining</w>
in organic</w>
cr imin
cholester ol,</w>
c e.</w>
apomorph ine</w>
P C</w>
M olecular</w>
-1 2</w>
ycl ic</w>
vari ed</w>
troph ic</w>
syn cop
m ast</w>
load ing</w>
isoniaz id</w>
ine ur
glob ulin</w>
fol ic</w>
bro ad</w>
allel ic</w>
IL -1</w>
Hg Cl
H odg
6 0%</w>
ro se</w>
prec linical</w>
platel et
m L</w>
ex ce
ester ase</w>
ep tion</w>
de part
bromocript ine</w>
b uc
analog ues</w>
PTE N</w>
5-az a-
transfer ases</w>
trans port
tiv es</w>
parox et
oc al
modi fi
mo ti
anxi et
CR P</w>
z es</w>
tric hloro
sit u
keratin ocytes</w>
evalu able</w>
encod es</w>
e ph
coun ts</w>
cont ex
NSAID s</w>
Import antly,</w>
8 0%</w>
(P K
w hi
vect or</w>
succin ylchol
schedul e</w>
rat ing</w>
potenti ation</w>
poster ior</w>
mis sion.</w>
met a-
l es</w>
in stil
gu id
finding s,</w>
cortico steroid</w>
ab or
W e
T T</w>
DO X
Cs A</w>
(N O
t or
surviv in</w>
secre ted</w>
ri tic</w>
om es</w>
mg/ day)</w>
inf or
h n
ey e</w>
diseas es,</w>
deteri oration</w>
def ense</w>
cholester ol
c. v
atheroscler otic</w>
apol ipo
T ol
PPA R</w>
Cell s</w>
A u
underg o</w>
scre ened</w>
rig idity</w>
pepti des</w>
in otropic</w>
haz ard</w>
glucuron idation</w>
furo semide</w>
frag ment
flavon oids</w>
diet .</w>
all oc
NQO 1</w>
1 C
stopp ed</w>
pre- treatment</w>
os ,</w>
granul e</w>
cyto k
chrom osomal</w>
behavi ors</w>
ba ro
a y
a sic</w>
a er
Tran si
O b
I CAM-1</w>
Gl uc
9 0%</w>
8 /
4- hydroxy
(GSH )</w>
valid ated</w>
tumour s</w>
tr am
sour ce</w>
prop ion</w>
pi per
neg atively</w>
ant ine
VKOR C1</w>
Ther ap
J an
G B
1, 25-
pa ir
mechanis tic</w>
benzo [a]
allow ed</w>
CYP2 E
0.000 1).</w>
(4 0</w>
( range,</w>
venti l
neg ati
necro tic</w>
min ute</w>
if or
cl onic</w>
bi otic</w>
IL- 6,</w>
A M</w>
week ,</w>
trac he
predomin ant</w>
opi oid
nec k</w>
bl un
anti- cancer</w>
adi po
II I
D ),</w>
3. 5</w>
(CYP )</w>
xenograf t</w>
valu es.</w>
tur no
ter but
sy novi
selec tivity</w>
re activation</w>
p h</w>
ouab ain</w>
i ans</w>
dis crimin
d ynamic</w>
bl ind
beli eved</w>
az one</w>
aw are</w>
arachid onic</w>
P X
Anim als</w>
AP L</w>
1 %,</w>
wid es
tr aining</w>
sp le
per man
medi al</w>
inf ant</w>
fol d
ffic acy</w>
c G
bcl -2</w>
arg in
a b</w>
TH P-1</w>
RS V</w>
tom ography</w>
monke ys</w>
le ts</w>
immunohist ochemistr
imid az
gest ational</w>
epti de</w>
depend ing</w>
benzodi azep
assa ys,</w>
G AD
C D</w>
Ang i
3 0,</w>
17 .
)- mediated</w>
ti car
scre en</w>
lo fen</w>
it ,</w>
iso form
fact ory</w>
dos ages</w>
at ed
an e-
N K</w>
MMP- 2</w>
M G</w>
AMP K</w>
signal ing,</w>
m E
immunoprecip itation</w>
frag ment</w>
fix ed</w>
first- line</w>
ble .</w>
ane l</w>
al low</w>
ain ide</w>
afen ib</w>
RP )</w>
P a
O A</w>
My ocardial</w>
J AK
HI V-
7 0%</w>
5 %,</w>
0 .</w>
sensitiv ity.</w>
nephro toxicity.</w>
gli oblastoma</w>
fibroblast s.</w>
duc t</w>
deple ted</w>
PAR P</w>
1. 3</w>
, p
(P I
ze braf
y /
tri als.</w>
thic kn
proced ure</w>
preven tive</w>
paraqu at</w>
os a</w>
micromol/ L</w>
l y-
k i
facilit ate</w>
cap illary</w>
atri oventricular</w>
arrhythmi as.</w>
V T</w>
Th us</w>
In v
Hepati c</w>
H R</w>
C s</w>
scler osis</w>
pot ently</w>
polymorph ic</w>
ne arly</w>
id al</w>
h O
col chic
Ne ph
Ev idence</w>
8 4</w>
un it</w>
suc c
sp ac
s he
paracetam ol</w>
ox ane</w>
k ain
hepat otoxicity.</w>
depend ent,</w>
aspec ts</w>
analyz ed.</w>
T otal</w>
I kappa
DN F</w>
D MA
CF TR</w>
29 3</w>
( median</w>
( NA
worsen ing</w>
v ic
teste d.</w>
rec essive</w>
mod est</w>
l umb
in yl</w>
ascor bic</w>
ar ch
L ith
CYP2C9 *
1 -1
(1 )-
(0. 1</w>
pro apoptotic</w>
malondi aldehyde</w>
fol d)</w>
f ever</w>
em i
cir cum
can ine</w>
bro mo
VD R</w>
Subjec ts</w>
STUD Y</w>
N- nitros
L os
ter .</w>
phenobarb it
oxal i
myel oper
estim ate</w>
der ,</w>
basel ine,</w>
Vit amin</w>
K O</w>
(II )</w>
pre term</w>
parti cles</w>
ol )</w>
nitr ite</w>
nause a,</w>
develop ment,</w>
c ade</w>
ac cur
V ari
TRPV 1</w>
Prote in</w>
D ep
Ca2 +
C is
Al ter
(I F
(H O
(E GF
t esticular</w>
opi ate</w>
ex act</w>
ax onal</w>
ac k</w>
H 1</w>
y ),</w>
t ation</w>
suppor ting</w>
mesoth eli
fibro tic</w>
et ing</w>
d ap
cas cade</w>
T i
O H</w>
J urk
synergis tically</w>
om er</w>
n e</w>
mo zol
li pos
hist ologic</w>
gre at</w>
factor .</w>
em ent.</w>
diaph rag
con stric
com promis
ag es,</w>
adri amycin
ad mission</w>
R ho
O D</w>
MG MT</w>
MDA-MB-2 31</w>
I f</w>
CX CL
(a )
well- known</w>
sequ ent</w>
m t
los s.</w>
lo be</w>
kill ed</w>
kidne y.</w>
in active</w>
electro ly
chemo therapy,</w>
aro und</w>
affec ted.</w>
aden o
T S</w>
O- de
E fficacy</w>
Combin ed</w>
7 ),</w>
resveratro l.</w>
rele ase,</w>
patient s)</w>
ome gal
nat urally</w>
mut ations.</w>
individu als.</w>
encod ed</w>
az ol</w>
antin ociceptive</w>
ab ly,</w>
] )</w>
(A s
( 5-FU
wides pread</w>
qu al
nex t</w>
ir lu
ex tre
cy an
calcit ri
ase /
arb oxyl
Oxid ative</w>
H(2)O (2)</w>
Ei gh
7 /
50 )</w>
2 %,</w>
( the</w>
som atic</w>
phosphatidyl inositol</w>
micro arra
log istic</w>
c d
Res pon
P R</w>
I R</w>
Hep at
G A</w>
( in</w>
u ary</w>
transcrip tion.</w>
tra ffic
p anel</w>
my alg
indic es</w>
id ,</w>
enzyme .</w>
C V
3, 4-
temper ature</w>
st ren
mozol om
medic ation.</w>
lin ed</w>
hydrochlorothiaz ide</w>
U DCA</w>
u tility</w>
struct urally</w>
st atic</w>
salic yl
s well
rout ine</w>
prob able</w>
on olact
mul tivariate</w>
lys osomal</w>
kidne y,</w>
evalu ating</w>
consider able</w>
M od
L-NA ME</w>
E stro
B A
AT )</w>
(R T-
y ].</w>
me tric</w>
loc al
interleukin -1
in tub
high- risk</w>
concentration -
U9 37</w>
T M
Re ver
Me dian</w>
In trac
F 2</w>
1 16</w>
surviv al,</w>
signific ant.</w>
present ation</w>
mal e
leuk ocyte</w>
excit atory</w>
ex in</w>
dail y,</w>
consc i
cl as
Transi ent</w>
IN D
C at
B P-
0. 8</w>
( ME
op ir
o der
it s,</w>
capsaic in-induced</w>
an il
aggra v
Un der</w>
T C</w>
PR L</w>
Ad ri
14 ,</w>
wor ld
thym idine</w>
sev o
sacrific ed</w>
resem bl
resc ue</w>
por t</w>
om od
obstruc tive</w>
obser ved,</w>
is op
contr action</w>
but yl
alpha -induced</w>
album in
Pr im
For ty-
F os</w>
yr in</w>
remo val</w>
quin idine</w>
p ect
moder ately</w>
impro ving</w>
id in</w>
correc ted</w>
as one</w>
R I
CC 1</w>
0. 7</w>
respon ding</w>
pro be</w>
pressu res</w>
ische mi
em b
benz yl
b yp
apparen tly</w>
abol ic</w>
UGT 2B
G SH
A spir
8 9
7 9
( a)</w>
revie we
pos t</w>
myocardi um</w>
mo stly</w>
mg/m (2)</w>
it y-
incorpor ation</w>
in ation</w>
e z
defec tive</w>
contro ver
cont ain</w>
cisplat in,</w>
chro mium</w>
cell s:</w>
amplit ude</w>
ac ut
S ER
Nor thern</w>
NO S)</w>
( 0
w ash
val ve</w>
tumori genesis</w>
spati al</w>
s.c .)</w>
re uptake</w>
pos ing</w>
phenotyp e.</w>
oste osarcoma</w>
midd le</w>
k in</w>
inc re
etopo side</w>
elucid ated.</w>
an ch
SC C</w>
MR I</w>
Identi fication</w>
H 2</w>
trigg er</w>
st y
retro viral</w>
nephro toxic</w>
is ing</w>
in direct</w>
d- release</w>
cont ains</w>
cat eg
anti biotic</w>
PC B</w>
P ot
F ox
CD 8
( VEGF
shi f
ma x</w>
ine ;</w>
diam eter</w>
deliri um</w>
abs ent</w>
a ur
T ER
D AT
(M T
vancom ycin</w>
under li
th es
sub typ
respectively ;</w>
prepar ations</w>
miR -1
lis in
gest ation</w>
ge fit
erythro cyte</w>
acid -
RA )</w>
NB 4</w>
II )</w>
H C</w>
Cp G</w>
C yclo
(RT- PC
spectrometr y</w>
re infor
ocicep tion</w>
knowledg e</w>
g avage</w>
famil y,</w>
exp an
clopidog rel</w>
c )</w>
ator ,</w>
R- mediated</w>
R ating</w>
PC -3</w>
MRP 1</w>
MAP K
M T-
EX P
C/ E
C M</w>
A mi
x y
ventric le</w>
plas min
perf used</w>
o protective</w>
mum ol/
lu tion</w>
k -
ep oxide</w>
diz zin
cadher in</w>
am ant
Q -
PA H
M Y
sur vi
prom p
peop le</w>
pa infu
painfu l</w>
neuro transmit
nanop articles</w>
mix t
mi R-
ithro mycin</w>
exten sively</w>
ede ma,</w>
bilirub in</w>
b p</w>
aud itory</w>
adip onectin</w>
N .</w>
1 a
tachycardi a.</w>
seem ed</w>
osom es</w>
ng/m l</w>
micro M),</w>
methyl phen
extrem ely</w>
doxorubic in.</w>
detec ted.</w>
derm atitis</w>
contribut ed</w>
TI MP
S K-
2- fold</w>
ul ate</w>
system s.</w>
sim ple</w>
s lic
regar d
hi m
half- life</w>
dop a</w>
dail y.</w>
bezaf ibrate</w>
arach no
